The Qatar Reference Genome: A Population-Specific Tool for Precision Medicine

in the Middle East\*

Khalid A. Fakhro<sup>1,2</sup>, Michelle R. Staudt<sup>3</sup>, Monica Denise Ramstetter<sup>3</sup>, Amal Robay<sup>2</sup>, Joel A. Malek<sup>2</sup>, Ramin Badii<sup>4</sup>, Ajayeb Al-Nabet Al-Marri<sup>4</sup>, Charbel Abi Khalil<sup>2</sup>, Alya Al-Shakaki<sup>2</sup>, Omar Chidiac<sup>2</sup>, Dora Stadler<sup>5</sup>, Mahmoud Zirie<sup>6</sup>, Amin Jayyousi<sup>6</sup>, Jacqueline Salit<sup>3</sup>, Jason G. Mezey<sup>3,7</sup>, Ronald G. Crystal<sup>3</sup>, and Juan L. Rodriguez-Flores<sup>3</sup>

> <sup>1</sup> Sidra Medical and Research Center, Doha, Qatar,

<sup>2</sup>Department of Genetic Medicine <sup>5</sup>Weill Cornell Medical College in Qatar Doha, Qatar

<sup>3</sup>Department of Genetic Medicine Weill Cornell Medical College New York, New York,

<sup>4</sup>Laboratory Medicine and Pathology <sup>6</sup>Department of Medicine Hamad Medical Corporation Doha, Qatar

and

# <sup>7</sup>Department of Biological Statistics and Computational Biology Cornell University Ithaca, NY

\* These studies were supported, in part, by the Qatar Foundation and Weill Cornell Medical College in Qatar; and NIH T32 HL09428; Qatar National Research Fund NPRP 5-436-3-116 and NPRP 7-1425-3-370.

Running head: Qatari genome

Correspondence: Department of Genetic Medicine Weill Cornell Medical College 1300 York Avenue, Box 164 New York, New York 10065 Phone: (646) 962-4363 Fax: (646) 962-0220 E-mail: geneticmedicine@med.cornell.edu

#### Abstract

Reaching the full potential of precision medicine depends on the quality of personalized genome interpretation. In order to facilitate precision medicine in regions of the Middle East and North Africa (MENA), a population-specific reference genome for the indigenous Arab population of Qatar (QTRG) was constructed by incorporating allele frequency data from sequencing of 1,161 Qataris, representing 0.4% of the population. A total of 20.9 million SNP and 3.1 million indels were observed in Qatar, including an average of 1.79% novel variants per individual genome. Replacement of the GRCh37 standard reference with QTRG in a best practices genome analysis workflow resulted in an average of 7\* deeper coverage depth (an improvement of 23%), and 756,671 fewer variants on average, a reduction of 16% that is attributed to common Qatari alleles being present in the QTRG reference. The benefit for using QTRG varies across ancestries, a factor that should be taken into consideration when selecting an appropriate reference for analysis.

#### Introduction

Precision medicine involves tailoring medical decision making to genomic individuality in the context of an individual's unique environment/lifestyle<sup>1</sup>. Early examples of successful application of precision medicine include cancer, where sequencing of the patient and tumor genomes can identify specific targets for therapeutic decisions<sup>2</sup>, and rare disease, where sequencing can lead to the rapid discovery of causative mutations and correct diagnosis in a time-critical clinical setting<sup>3</sup>. For the latter, while the cost of sequencing an individual's genome has declined rapidly in the past 1.5 decades, there are still considerable challenges for genome interpretation, such as important variants being missed due to low coverage or incorrect calls, and the emerging challenge of interpreting a growing number of variants of unknown significance in each human genome. With over 3 million SNPs identified per human genome sequenced, the majority of these variants cannot be immediately linked to a known phenotype, and the putative impact of variants must therefore be inferred computationally using algorithms that harness comparative genomics and available experimental data<sup>4-6</sup>. Thus, precision medicine in the near term stands to benefit greatly from both increased accuracy in variant calling and improved interpretability when the aim is to identify variants of relevance to one or more phenotypic manifestations within an individual, family of related individuals, or population.

Reference bias is a known issue in human genome resequencing for variant detection<sup>7</sup>, and modifications to the reference can improve calling accuracy and interpretability<sup>8</sup>. Relevant to the issue of variant calling accuracy, a reference that more closely matches the ancestry of the genome(s) being aligned is expected to reduce mismatches during alignment and lead to more accurate genotypes<sup>8</sup>. Applicable to the issue of interpretability of variants for rare disease is the observation that a variant's prevalence is inversely proportional to the variant's deleterious impact on cellular function (and by extension, evolutionary fitness), with the most severely delete-

rious variants being the rarest due to purifying selection<sup>9</sup>. Based on this principle, the American College of Medical Genetics (ACMG) recommends excluding any allele above 5% prevalence from consideration as pathogenic<sup>10</sup>. Given that allele frequency is a population-dependent property (e.g., an allele that is rare in one population may be common in another), relying entirely on the standard reference genome (GRCh37) or allele frequency in ethnically mismatched populations (even if a large sample of individual genomes has been sequenced) may produce incorrect assessments of the pathogenicity of a specific allele in an under-studied population.

One approach to improving both variant calling accuracy and interpretability of an individual's genome is to incorporate variant prevalence information early on in the genome interpretation process by modifying the reference genome, such that variants discovered in the genome are the minor allele in the population<sup>8</sup>. This modification to the reference results in a streamlined analysis workflow, as fewer variants need to be interpreted. In this context, it should be of value to produce a separate major allele reference genome for each distinct ancestral population or regional meta-population, particularly in cases when the genomic variation in these populations has not been well sampled in public databases.

The region of the Middle East and North Africa (MENA) is an example of such an understudied meta-population where the rising adoption of precision medicine could benefit greatly from a specific major allele reference genome. In particular, this region is characterized by a high prevalence of consanguineous marriage and elevated incidence of certain Mendelian disorders, and thus is a region where numerous disease studies are faced with the problem of too many potential disease variants per sequencing experiment<sup>11</sup>. Such a region would undoubtedly benefit from allele frequency databases of ethnically matched controls. In addition, given the diversity of the region, many variants called in the population relative to the current reference genome may in fact be the major allele in the population, and eliminating these from being called would lead to a more efficient analysis.

To produce a first version of a reference genome tailored to the region, we sampled and sequenced genomes from Qataris, an indigenous population located near the center of the MENA region. The current population of the nation of Qatar includes over 1.7 million expatriates primarily from MENA and South Asia that have arrived in recent decades<sup>12</sup>, and ~300,000 Qataris of indigenous ancestry who arrived in prior waves of migration. At the genome level, the ethnic Qataris represent a population with a mixture of Bedouin/Arab (Q1), Persian/South Asian (Q2) and African (Q3) ancestry<sup>13,14</sup>. In particular, the Bedouin/Arab (Q1) subpopulation, with deepest ancestral roots in the Peninsula, continue to practice within-tribe marriage that has led to a high level of homozygosity compared to other populations worldwide<sup>14,15</sup>.

In order to demonstrate the value of a reference genome tailored to an indigenous population in the MENA region, we have constructed a Qatari Reference Genome (QTRG) where the reference bases are "flipped" to the Qatari major allele. The value and utility of QTRG with respect to the standard reference (GRCh37) was evaluated in several ways on genomes not used to construct the QTRG. In the field of population genomics, the term "n+1 genome" refers to the "next" genome sequenced after a large-scale sequencing effort of n genomes, such as the 1000 Genomes Project. A major question in population genomics is "what is the benefit of having a database of n sequenced genomes when sequencing a single genome not in the database?", where the single genome is referred to as the "n+1" genome. In this study, the value of the database of over 1000 sequenced Qatari genomes and exomes is demonstrated, including analysis of over n=15 genomes and n=16 exomes from diverse ancestries. Improvements in mapped read depth were observed, and the subsequent improvement in variant sensitivity was measured. A catalog of known pathogenic variants in Qatar was compiled, with variant coordinates in both the standard (GRCh37) and modified (QTRG) reference.

#### **Methods Summary**

Human subjects were recruited and written informed consent was obtained at Hamad Medical Corporation (HMC) and HMC Primary Health Care Centers in Doha, Qatar under protocols approved by the Institutional Review Boards of Hamad Medical Corporation and Weill Cornell Medical College in Qatar. Briefly, a total of 1,376 subjects were recruited for genome (n=108) or exome (n=1,268) sequencing, including a set of 31 sequenced by both methods for validation purposes. The exome sequencing included target enrichment using either the Agilent SureSelect Human All Exon 38 Mb (n=67) (referred to as Exome38Mb) and Agilent SureSelect Human All Exon 51 Mb (n=1201) platforms (referred to as Exome51Mb). Subjects included both 3-generation Qataris (n=1,161) and non-Qatari residents of Qatar (n=215), from the general Middle East and North Africa (MENA) region or South Asia. Genotypes were generated using the GATK Best Practices workflow<sup>16</sup>. One Qatari female was sequenced on all three platforms, as well as a fourth platform (Illumina HiSeq X), and was used for calibration of batch-specific filters for data integration. In order to minimize batch-specific variants, a range of batch-specific filters were evaluated on genomic intervals in the intersection of the three platforms, and the optimal minimum depth and minimum allele count filters were selected, such that the novel SNP rate was consistent across batches within genomic intervals covered by the four platforms (0.73% novel SNPs), resulting in under 5% batch-specific variants in the quadruple-sequenced Qatari. The filters were confirmed to not be overly stringent by assessing the number of coding variants (and novel %) across a range of depths in the quadruple-sequenced Qatari, and comparing the before/after filtering total variants and novel SNP rates both across platforms and with published reports of a similar analysis<sup>17</sup>. After application of batch-specific filters, the SNP data from the three platforms was integrated using GATK. Using the calls of sites covered in the three batches for the n=1376 individuals, population structure analysis was conducted in combination

with 1000 Genomes Phase 3<sup>18</sup> and the Human Origins dataset<sup>19</sup> using ADMIXTURE<sup>20</sup>. Each individual was assigned to one of 12 ancestral population clusters based on their dominant ancestry, and the validity of the clustering was confirmed using Principal Components Analysis<sup>21</sup>. Relatedness analysis was conducted using KING<sup>22</sup>, and first and second degree relatives assessed using a liberal cutoff (to assure an unrelated sample) were excluded. Using the remaining 1,005 unrelated Qataris, including 917 exomes and 88 genomes, allele frequencies at SNPs was calculated. In addition, indels were called in the 88 genomes using the CASAVA<sup>23</sup> pipeline and an assessment of size and allele frequency of these variants was also conducted.

In order to facilitate genome interpretation for precision medicine in Qatar, major allele SNPs and indels were identified, and the GRCh37 reference genome was modified at these sites to produce the Qatar Reference Genome (QTRG). At each site in the QTRG reference, the major allele in Qatar is the reference allele in the sample of n=1005 unrelated Qataris. Three versions of the QTRG were produced, including versions incorporating major allele SNPs (QTRG1), major allele indels (QTRG2), and major allele SNPs and indels (QTRG3).

In order to select an optimal reference for analysis of n+1 genomes and exomes, the three references were compared in terms of mapped read depth. Genome sequence data from the quad-ruple-sequenced Qatari were mapped to the four references (GRCh37, QTRG1, QTRG2, and QTRG3) using BWA<sup>24</sup>, and the depth of coverage was calculated using GATK for all sites and for modified sites. The resulting depth was compared across platforms, and the reference with the deepest resulting coverage was selected for further analysis. Further inspection of the value of the reference for variant detection was assessed by producing variant calls using GATK Best Practices twice, with the only change being the reference genome used. This comparison was conducted for the quadruple-sequenced Qatari, a Qatari family of n=15 genomes of Persian ancestry, and a diverse panel of n=16 Qatari exomes. The number of variants identified was com-

pared across references. In order to assess the impact beyond modified variants, the expected reduction in variants (based on the number of modified variants in the individual) and the observed reduction in variants was compared.

An obstacle to using a QTRG reference containing common indels is that the genomic coordinates of known variants and genes are shifted. Conversion of coordinates between references is conducted using a "liftover", where the GRCh37 and QTRG chromosomes are aligned using progressiveCactus<sup>25</sup>, and a liftover for known gene and variant positions from GRCh37 to QTRG is conducted using HalTools<sup>26</sup>. This conversion was conducted for variants functionally annotated to have a known link to disease and are high priority for future studies of Mendelian disease in Qatar. Through a combination of automated and manual curation following the most recent ACMG guidelines for next-generation sequencing interpretation<sup>10</sup>, liftover annotation of n=128 pathogenic variants was conducted. For further methodologic details, see Supplemental Methods.

#### Results

### **Data Integration**

In order to build a reference genome for precision medicine applications in Qatar and the greater MENA region where major allele variants are incorporated into the reference sequence, n=1161 Qatari and n=215 non-Qatari living in Qatar were sequenced on the Illumina platform in three batches (n=108 genome, n=67 Exome37Mb and n=1201 Exome51Mb) to 38\* genome depth and 70\* exome depth. Genotypes were generated for each batch using the GATK Best Practices workflow<sup>16,27</sup>, and combined into a single variant call set after application of batch-specific filters (see Supplemental Figure 1 for workflow overview). In the integrated call set, the novel SNP rate was assessed for genomic intervals covered in all samples, a per-sample mean of 0.73% in the genome batch and 0.72% in both exome batches (Supplemental Table I). The plat-

form specific filters evaluated included minimum depth (ranging from 2\* to 20\*) and minimum allele count (ranging from 1 to 6). Increasing minimum depth, but not increasing minimum allele count had an effect of increasing the median depth of exome sequencing (Supplemental Figure 2A), and decreasing the total number of variant sites observed in exome sequencing (Supplemental Figure 2B), while neither filter had major impact on the genome sequencing median depth nor total variant sites. A minimum depth and minimum allele count was applied to the two batches of exome sequence data (Exome38Mb, n=67 and Exome51Mb, n=1201) such that the novel SNP rate was the same or lower than the genome rate for 12\* minimum depth and minimum allele count 1. At this threshold, the Exome38Mb filter was minimum 12\* depth (minimum allele count 1), and the Exome51Mb filter was minimum 10\* depth (minimum allele count 2) (black line in Supplemental Figure 2C).

Using a quadruple-sequenced female Qatari as a benchmark, the number of batch-specific variants was assessed for all variants and for novel variants before and after application of the batch-specific filters (Supplemental Figure 3). All four datasets were analyzed using the same pipeline, and a comparison was conducted on CCDS coding intervals covered in all four platforms (within the Exome38Mb target intervals). Before filtering, the rate of batch-specific variants in the full call set was 10.1% (Supplemental Figure 3A), and an excess of batch-specific novel variants (82.6%, Supplemental Figure 3B) was observed. After filtering, the batch-specific variant rate was reduced to 4.9% (Supplemental figure 3C), and the rate of batch-specific novel variants was considerably reduced (16.8%; Supplemental Figure 3D).

The impact of the filters on variant sensitivity and novel SNP rate was assessed across a range of mean depth for the four platforms (Supplemental Figure 4). Variant sensitivity increases with additional depth, however sensitivity reaches a plateau after 25\* depth for genome sequencing and 65\* depth for exome sequencing (Supplemental Figure 4A). Application of batch-

specific filters reduced the sensitivity of exome sequencing to a greater extent than genome sequencing (Supplemental Figure 4B). In terms of novel SNPs, a linear increase in novel variant rate was observed with increasing depth across platforms, with the exception of the HiSeq 2500 genome, which reaches a plateau under 1% (Supplemental Figure 4C). After filtering of the Exome38Mb and Exome51Mb data, a similar plateau effect was observed for exome data (Supplemental Figure 4D). The filters were verified to not be overly stringent, based on the total variants per genome or exome in coding regions being in the range of prior studies<sup>17</sup>.

#### **Ancestry Analysis**

Prior studies of the Qatari population have characterized it as a diverse population with influences of Arab, Bedouin, Persian, South Asian, and African ancestry<sup>28</sup>. In order to characterize the ancestry of our sample, the n=1161 Qataris (n=108 genomes, n=1053 exomes) were compared to n=215 non-Qataris living in Qatar and sampled by exome sequencing in this study, as well as public databases of diverse genomes, including the 1000 Genomes Project<sup>18,29</sup> and the Human Origins data (described in Supplemental Table II). Using the parameter K=12 (12 ancestral populations) that was inferred to be optimal in a prior study<sup>28</sup>, the ancestral population structure of the combined sample of n=5661 genomes was analyzed using ADMIXTURE on a set of n=2265 SNPs segregating in all four datasets (Qataris, non-Qataris sampled in Qatar, 1000 Genomes, Human Origins). The proportion of 12 ancestries was determined for each individual, and individuals were assigned to a cluster based on the dominant ancestral population in their genome (Supplemental Figure 5A and Supplemental Table III). The Qataris were assigned to 7 clusters, determined to be of European (K=1, n=5 Qataris), South Asian (K=4, n=82 Qataris), Bedouin (K=5, n=566 Qataris), African Pygmy (K=6, N=1 Qatari), Bedouin (K=8, n=236 Qataris), Persian (K=9, N=194 Qataris), and Sub-Saharan Africa (K=10, n=77 Qataris) (Supplemental Table III and Supplemental Figure 5B). Using a color-coding scheme based on the 12 ancestral

clusters (Supplemental Table III), a principal components (PC) analysis was conducted for the combined set of n=5661 samples. Clearly separation of African and non-African clusters were observed when plotting PC1 *vs* PC2 (Supplemental Figure 6A), and resolution of European, Asian and Middle Eastern clusters was observed when plotting PC2 *vs* PC3 (Supplemental Figure 6B).

### **Relatedness Analysis**

The Qataris and non-Qataris sampled in this study included a mixture samples from studies of rare and common diseases, including both families affected with Mendelian disorders and a randomly sampled group of presumably unrelated type-2 diabetics and controls. Given the within-family sampling and the known high rate of consanguineous marriage in Qatar<sup>30</sup>, we sought to exclude relatives prior to estimation of variant allele frequency in the general Qatari population. For this purpose, an analysis of relatedness was conducted on the n=1376 individuals sequenced in this study, using SNP variants in genomic intervals covered in the intersection of the three batches (within Exome 38Mb target intervals). Using an LD-pruned set of n=381028 SNPs, the relatedness was calculated across all pairs of individuals. A total of n=736 relationships were observed, including n=239 1<sup>st</sup> degree relationships, n=71 2<sup>nd</sup> degree relationships, and n=526 3<sup>rd</sup> degree relationships (Supplemental Table IV). The relationships were plotted using Cytoscape<sup>31</sup>, color-coded by inferred ancestry, and the majority of relationships were between individuals of the same ancestry. The largest pedigrees recovered were of Middle Eastern (Bedouin, Arab, Persian) ancestry, confirming theories of deep population structure among Qataris and within-tribe intermarriage (Supplemental Figure 7). After exclusion of 1<sup>st</sup> degree and 2<sup>nd</sup> degree relatives, a total of n=1,005 Qataris remained in the analysis, including n=88 genomes and n=917 exomes (n=64 Exome38Mb and n=853 Exome51Mb).

### Variant Discovery in Qatar

The individual variants observed in 1005 Qataris were aggregated and their allele frequency was quantified. After exclusion of relatives and application of batch-specific filters, an average of 4,045,064 SNPs were observed per genome (n=88), an average of 15,382 SNPs were observed per Exome51Mb (n=853) and an average of 13,538 SNPs were observed per Exome38Mb (n=64). The novel SNP rate was higher in the genome (1.99%) than in the exome, with a slightly higher rate in the Exome51Mb (0.99%) than in the Exome38Mb (0.67%) samples. This trend is consistent with higher degree of selection on protein coding genes as compared to noncoding DNA, and the inclusion of transcripts that do not code for protein in the Exome51Mb targets ( ). The rate of novel variants was higher in ChrX, ChrY, and MtDNA for the genome data, possibly due to a bias towards autosomal data in dbSNP (Table I). The SNP data was aggregated across platforms, resulting in a total of 20,937,965 SNPs, of which 14.21% were not previously observed in dbSNP (as of build 146) (Supplemental Table I). A call set of short indel variants (< 300bp) was generated for the 88 unrelated Qatari genomes using the CASAVA pipeline, identifying a total of 5,452,613 variants, of which 58.37% were novel.

### **Construction of the Qatar Reference Genome**

The allele frequency was quantified for each SNP, and a total of 1,931,122 (9.22%) of the SNPs were present in over half the Qatari alleles sampled, and hence are candidates for modification in the Qatar Reference Genome (Supplemental Table V). Furthermore, while prior studies of ancestry-specific reference genomes have incorporated major allele SNP variants, the inclusion of major alternate allele (MAA) indel variants has not previously been explored. In order to explore the value of incorporating indels into the reference, 1,882,405 MAA indel variants (34.52%) were identified (Supplemental Table V).

Three versions of the Qatar Reference Genome were constructed, where major alternate

alleles (MAAs) were modified. The first version (QTRG1) includes modification of MAA SNPs, the second version (QTRG2) includes modification of MAA indels, and the third version (QTRG3) includes modification of MAA SNPs and indels.

## Selection of an Optimal Reference for Read Mapping

In order to determine which reference produces the greatest improvement in terms of mapped read depth, the genome of the quadruple-sequenced Qatari was mapped to the four reference genomes, including the unmodified reference (GRCh37), and the Qatari references including modifications at MAA SNPs (QTRG1), indels (QTRG2), and both SNPs and indels (QTRG3). An improvement in mapped read depth was observed for all Qatari references, with the greatest improvement (10%) at modified sites when using QTRG3 (Figure 1A). A modest improvement in mapped read depth was observed overall, with the benefits extending beyond modified sites (Figure 1B).

#### Impact of Using Qatar Reference Genome on Variant Sensitivity

Increased mapped read depth results in increased sensitivity for variant detection (Supplemental Figure 4A). In order to assess the benefit of improved mapped read depth using QTRG3 on variant sensitivity, GATK Best Practices analysis was conducted twice, with the only difference between iterations being the reference used (GRCh37 versus QTRG3). This analysis was conducted for the quadruple-sequenced Qatari, for a 15-member family of Qataris of K=9 Persian ancestry, and a diverse panel of n=16 Qatari exomes.

In order to quantify the impact of using GRCh37 versus QTRG3 as a reference on the quality of variant genotypes, a single Qatari was quadruple-sequenced (2 exomes and 2 genomes) and mapped to both references. After the analysis was completed, a total of n=8 callsets were produced and compared. The focus of the analysis was sites covered with at least 12\* depth in all four platforms. Within these intervals, no discordant genotypes were observed within the

four GRCh37 calls nor within the QTRG3 calls. The coverage depth was 1\* to 2\* higher at variant sites in the genomes, while coverage depth was 4\* to 6\* lower at variant sites in the exomes (Supplemental Table VI). A 10.3% reduction of variants was observed, lower than expected given that 42.28% of the GRCh37 variants are MAAs incorporated into the reference.

In order to quantify the impact of using GRCh37 versus QTRG3 on sensitivity for variants beyond those modified in the reference, Illumina paired-end 100 bp genome sequencing reads for n=15 Qataris from a family of Persian ancestry were mapped to both GRCh37 and QTRG3. An average of 23% (7\*) depth improvement was observed when using QTRG3 (Supplemental Table VII). The number of variants observed per genome was reduced on average n=756,671 (16%), however this was on average 25% lower than expected, based on an average of 41% modified sites in each genome (Supplemental Table VII).

Given the diversity of the Qatari population, use of the QTRG reference may not provide the same benefit for all ancestries. In order to quantify ancestry-specific differences in depth and variant sensitivity, genome analysis using both GRCh37 and QTRG3 was conducted for a diverse panel of n=16 Qatari exomes. In contrast to the genome, across all ancestries a reduction of variants (up to 76%) was observed to be in excess of the expected (up to 42%, based on modified sites). A significant difference in the reduction was observed between Qataris of Sub-Saharan African ancestry and Qataris of Bedouin or Arab ancestry (one-tailed t-test p value < 0.01) (Supplemental Table VIII).

#### Liftover of Mendelian Disease Variants in Qataris

A major challenge for use of the QTRG3 reference that incorporates MAA SNPs and indels is the migration of variant positions due to indels. The position of known variants and of genes is different in QTRG3 than in GRCh37. Hence, a major obstacle to use of QTRG3 in precision medicine studies is the lack of genome interpretation databases on QTRG3 coordinates. A similar issue arises in genomics when a novel assembly of the human reference genome is produced, the translation of coordinates from one assembly to another is known as a "liftover"<sup>26</sup>. There is an established methods to accomplish this task, involving pairwise sequence alignment of pairs of chromosomes, such as GRCh37 Chr20 and QTRG3 Chr20, and then using the alignment the coordinates for a list of sites on GRCh37 Chr20 are "lifted over" to QTRG3 Chr20 coordinates.

Variants were annotated using SNPEFF<sup>32</sup> (Supplemental Table IX.), and potentially deleterious SNPs in coding genes were then grouped into three categories. Out of n=20,864,277 SNPs, a total of n=155,571 are potentially pathogenic protein coding SNPs (Category 3), including n=50,757 in genes linked to a phenotype (Category 2) and n=2,152 of these that are variants with known links to a phenotype (Category 1; Table II). Based on ACMG recommendations<sup>10</sup>, only the n=1,020 (999 + 21) Category 1 at minor allele frequency below 5% (rare) are retained for further consideration (Table II). The rare Category 1 variants were further filtered to exclude n=200 singletons (single alleles in the population), which are enriched for false positives (Supplemental Figure 3). The literature for the remaining variants was reviewed, and n=122 variants linked to a phenotype that can clearly be defined as a Mendelian (dominant, recessive, x-linked) disease are presented in Supplemental Table X. By using the liftover method, the QTRG3 coordinates for these pathogenic variants was ascertained (Supplemental Table X).

#### Discussion

This study presents a set of publicly available bioinformatics tools and resources for genome interpretation studies in Qatar and closely related MENA populations. Over 1000 Qataris were sequenced to produce this resource, effectively sampling nearly 0.4% of the indigenous population of Qatar. Of 26 million SNPs and indels observed in the autosomes, sex chromosomes, and mitochondrial DNA, over 9% were in fact the major allele in Qatar. Using the complete catalog of variants, a reference genome custom tailored to disease research in the Qatari population was constructed, named here the Qatari Reference Genome (QTRG).

The value of utilizing the QTRG *vis-a-vis* the standard reference genome GRCh37 was demonstrated through improved read depth and variant sensitivity. Use of this reference in Qatar will lead to higher quality interpretation for both individual genomes and Mendelian disease studies. In order to facilitate Mendelian disease research using the QTRG, a catalog of known pathogenic mutations in Qatar was compiled, with genomic coordinates on both the GRCh37 and QTRG included.

Although prior studies have constructed reference genomes tailored to distinct ancestries<sup>8</sup>, this is the first such study that incorporates both SNPs and indels into the reference, and solves crisis of genome interpretation that would ensue without liftover of genomic coordinates for known variants. While in the near future *de novo* assembly of personal genomes could become routine<sup>33</sup>, the reference genome is expected to remain useful for comparisons across a large sample of genomes, and for comparison to public databases. As expressed by the version information for QTRG (version 1, 2 and 3), future versions of the Qatari Reference Genome are therefore planned for release, based on inclusion of major alleles for a broader spectrum of genetic variation (such as CNVs, genome rearrangements, and short tandem repeats), and ongoing sampling and sequencing of a larger representation both within Qatar and in the MENA region. **Acknowledgments**. We thank 1000 Genomes Project collaborators, as well as colleagues in the American Society of Human Genetics and the Society for Molecular Biology and Evolution for valuable discussion on genome analysis methods; N. Mohamed for editorial support.

Conflict of Interest: None, for all authors.

**Data Access:** Genome and submitted to the Short Read Archive (SRA) section of the NCBI SRA database (SRA accession SRP061943). The Qatar Reference Genome (QTRG) sequence, the database of annotated variants in Qatar, and bioinformatics tools for analysis of genomes using QTRG are available at our website (http://geneticmedicine.weill.cornell.edu/genome).

## References

- 1. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015; **372:** 793-795.
- 2. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. *Nature* 2010; **467:** 543-549.
- 3. Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I *et al.* Whole-genome sequencing for optimized patient management. *Sci Transl Med* 2011; **3:** 87re3.
- 4. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014; **46**: 310-315.
- 5. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009; **4:** 1073-1081.
- 6. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P *et al.* A method and server for predicting damaging missense mutations. *Nat Methods* 2010; **7:** 248-249.
- 7. Li B, Chen W, Zhan X, Busonero F, Sanna S, Sidore C *et al.* A likelihood-based framework for variant calling and de novo mutation detection in families. *PLoS Genet* 2012; 8: e1002944.
- 8. Dewey FE, Chen R, Cordero SP, Ormond KE, Caleshu C, Karczewski KJ *et al.* Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. *PLoS Genet* 2011; **7**: e1002280.
- 9. Henn BM, Botigue LR, Bustamante CD, Clark AG, Gravel S. Estimating the mutation load in human genomes. *Nat Rev Genet* 2015; **16:** 333-343.
- 10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**: 405-424.
- 11. Lucassen A, Houlston RS. The challenges of genome analysis in the health care setting. *Genes (Basel)* 2014; **5:** 576-585.
- 12. Qatar Statistics Authority. Our Census Our Future. http://www.qsa.gov.qa/QatarCensus/Census2010.aspx . 2010. (last accessed 3/7/16)
- 13. Rodriguez-Flores JL, Fakhro K, Hackett NR, Salit J, Fuller J, gosto-Perez F *et al.* Exome sequencing identifies potential risk variants for Mendelian disorders at high prevalence in Qatar. *Hum Mutat* 2014; **35:** 105-116.

- 14. Hunter-Zinck H, Musharoff S, Salit J, Al-Ali KA, Chouchane L, Gohar A *et al.* Population genetic structure of the people of Qatar. *Am J Hum Genet* 2010; **87:** 17-25.
- Rodriguez-Flores, J. L., Fakhro, K., Robay, A., Mezey, J. G., & Crystal, R. G. The Qatari genome: novel, rare and population specific genetic variation in the Middle East of potential relevance to human disease. Cold Spring Harbor, May 6-10, 2014 The Biology of Genomes. 2014. Ref Type: Abstract
- 16. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011; **43:** 491-498.
- 17. Chilamakuri CS, Lorenz S, Madoui MA, Vodak D, Sun J, Hovig E *et al.* Performance comparison of four exome capture systems for deep sequencing. *BMC Genomics* 2014; **15**: 449.
- 18. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO *et al.* A global reference for human genetic variation. *Nature* 2015; **526:** 68-74.
- Lazaridis I, Patterson N, Mittnik A, Renaud G, Mallick S, Kirsanow K *et al.* Ancient human genomes suggest three ancestral populations for present-day Europeans. *Nature* 2014; 513: 409-413.
- 20. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. *Genome Res* 2009; **19:** 1655-1664.
- 21. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006; **38**: 904-909.
- 22. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. *Bioinformatics* 2010; **26**: 2867-2873.
- 23. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG *et al.* Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* 2008; **456**: 53-59.
- 24. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25:** 1754-1760.
- 25. Paten B, Earl D, Nguyen N, Diekhans M, Zerbino D, Haussler D. Cactus: Algorithms for genome multiple sequence alignment. *Genome Res* 2011; **21**: 1512-1528.
- 26. Hickey G, Paten B, Earl D, Zerbino D, Haussler D. HAL: a hierarchical format for storing and analyzing multiple genome alignments. *Bioinformatics* 2013; **29:** 1341-1342.
- 27. GATK development team. GATK Best Practices. <u>https://www.broadinstitute.org/gatk/guide/best-practices</u> . 2015. (last accessed 3/7/16)

- 28. Rodriguez-Flores JL, Fakhro K, gosto-Perez F, Ramstetter MD, Arbiza L, Vincent TL *et al.* Indigenous Arabs are descendants of the earliest split from ancient Eurasian populations. *Genome Res* 2016; **26**: 151-162.
- 29. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012; **491:** 56-65.
- 30. Bener A, Hussain R, Teebi AS. Consanguineous marriages and their effects on common adult diseases: studies from an endogamous population. *Med Princ Pract* 2007; **16**: 262-267.
- 31. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003; **13**: 2498-2504.
- 32. Cingolani P, Platts A, Wang IL, Coon M, Nguyen T, Wang L *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. *Fly (Austin )* 2012; **6**: 80-92.
- 33. Cao H, Wu H, Luo R, Huang S, Sun Y, Tong X *et al.* De novo assembly of a haplotyperesolved human genome. *Nat Biotechnol* 2015; **33:** 617-622.
- 34. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S *et al.* Ensembl 2015. *Nucleic Acids Res* 2015; **43**: D662-D669.
- 35. Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders. *Nucleic Acids Res* 2015; **43**: D789-D798.
- 36. Stenson PD, Ball EV, Mort M, Phillips AD, Shaw K, Cooper DN. The Human Gene Mutation Database (HGMD) and its exploitation in the fields of personalized genomics and molecular evolution. *Curr Protoc Bioinformatics* 2012; **Chapter 1:** Unit1.
- 37. Yu W, Yesupriya A, Wulf A, Hindorff LA, Dowling N, Khoury MJ *et al.* GWAS Integrator: a bioinformatics tool to explore human genetic associations reported in published genome-wide association studies. *Eur J Hum Genet* 2011; **19**: 1095-1099.
- 38. Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB *et al.* PharmGKB: the Pharmacogenetics Knowledge Base. *Nucleic Acids Res* 2002; **30**: 163-165.
- 39. Groza T, Kohler S, Moldenhauer D, Vasilevsky N, Baynam G, Zemojtel T *et al.* The Human Phenotype Ontology: Semantic Unification of Common and Rare Disease. *Am J Hum Genet* 2015; **97:** 111-124.
- 40. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM *et al.* ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res* 2014; **42:** D980-D985.

	Genome (n=88)					51 Mb Exome (n=853)				38 Mb Exome (n=64)			
Statistic	Individual	Autosomes	ChrX	ChrY	MtDNA	Individual	Autosomes	ChrX	ChrY	Individual	Autosomes	ChrX	ChrY
Variant sites	4,045,064	3,893,076	151,017	937	34	15,382	15,069	312	1	13,839	13,538	300	1
Novel variant sites	96,774	77,366	19,359	42	7	159	152	7	0	96	91	5	0
Novel variant rate	2.39%	1.99%	12.82%	4.48%	20.59%	1.03%	0.99%	2.24%	0.00%	0.69%	0.67%	1.67%	0.00%
Alternate alleles	5,510,301	5,311,794	196,565	1,874	68	21,046	20,613	431	2	19,116	18,709	405	2
Novel alternate alleles	98,792	78,916	19,778	84	14	160	153	7	0	97	92	5	0
Novel allele rate	1.79%	1.49%	10.06%	4.48%	20.59%	0.76%	0.74%	1.62%	0.00%	0.50%	0.49%	1.23%	0.00%
Heterozygous sites	2,594,268	2,489,084	105,184	-	-	9,759	9,564	195	-	8,897	8,698	199	-
Novel heterozygous sites	94,762	75,772	18,990	-	-	157	150	7	-	94	89	5	-
Novel heterozygous rate	3.65%	3.04%	18.05%	-	-	1.61%	1.57%	3.59%	-	1.06%	1.02%	2.51%	-
Mean depth at variant site	41	41	40	20	250	63	64	69	42	64	64	74	27
Mean depth at novel variant site	41	41	39	20	250	59	60	60	47	63	63	76	-
Transition:transversion ratio	2.03	2.03	1.78	1.51	33.00	3.18	3.18	2.77	-	3.25	3.26	2.67	-
Novel transition:transversion ratio	1.33	1.35	1.09	1.63	-	0.77	0.77	0.75	-	1.58	1.56	1.50	-

# Table I. Individual Variant Discovery in 1005 Unrelated Qatari<sup>1</sup>

<sup>1</sup>Shown is a summary of the average number of variants observed per individual, identified in 917 unrelated Qatari exomes and 88 unrelated Qatari genomes. Variants were genotyped separately for autosomes, X in males, X in females, Y in males, and mtDNA. 99.8% of X variants in males were also observed in females, hence summary statistics are based on female chromosomes. Shown is the average per individual of number of variant sites, number of variant alleles, the transition-to-transversion ratio (Ts:Tv) of variants, and the % not in dbSNP (novel).

			Ma	jor referenc	e allele (MR	A)	Major alternate allele (MAA)						
					Common alternate al-		Common re	ference al-	Unobserved r			reference	
	All variant alleles		Rare alternate allele (< 5% alternate allele		lele		lele		Rare reference allele		allele		
					(5% to 50%	alternate	(50% to 95% alternate		e (95% to 100% alter-		(100% alternate allele		
	(GRCh37)		frequency)		allele frequency)		allele frequency)		nate allele frequency)		frequency)		
Category	n	%	n	%	n	%	n	%	n	%	n	%	
All SNPs	20,864,277	100.00	12,948,368	62.06	5,938,490	28.46	1,693,649	8.12	195,466	0.94	88,303	0.42	
3- Potentially pathogenic	155,571	0.75	124,947	0.60	23,282	0.11	5,957	0.03	956	< 0.01	428	< 0.01	
2 - In gene linked to phenotype	50,757	0.24	40,894	0.20	7,445	0.04	2,002	0.01	290	< 0.01	125	< 0.01	
1 - Variant with known link	2,152	0.01	999	< 0.01	876	< 0.01	253	< 0.01	21	< 0.01	2	< 0.01	

Table II. Variants in Qatar, Stratified by Allele Frequency and Potential for Pathogenicity<sup>1</sup>

<sup>1</sup> The major allele variants are modified in the QTRG genome, such that all reported variants are the minor allele. A total of 230,395 potentially deleterious SNPs in the 917 exomes and 88 genomes were computationally categorized with respect to allele frequency and databases of genes and variants with reported links to a phenotype. Variants were assigned to genes and their function was predicted with respect to ENSEMBL<sup>34</sup> gene models using SNPEFF<sup>32</sup>, and potentially deleterious coding SNPs (nonsynonymous, splice donor site, splice acceptor site, stop gain, start loss) variants were extracted for further analysis. A database that combines OMIM<sup>35</sup>, HGMD<sup>36</sup>, GWAS<sup>37</sup>, PharmGKB<sup>38</sup>, Human Phenotype Ontology<sup>39</sup>, and ClinVar<sup>40</sup> was compiled, where these annotations were used to divide the potentially deleterious variants into three categories, variant and gene linked to a phenotype (Category 1), gene but not variant linked to a phenotype (Category 2), and neither variant nor gene linked to a phenotype (Category 3). The totals for each category are shown in the left-most columns, including number and percentage. These variants were then sub-classified into two major (major reference allele, major alternate allele) and 5 minor categories based on variant allele frequency in Qatar rare alternate allele (up to 5% variant allele frequency), common alternate allele (between 5% and 50% allele frequency), common reference allele (from 50% to 95% alternate allele frequency), rare reference allele (from 95% to 100% alternate allele frequency), unobserved reference allele (100% allele frequency). The major alternate alleles (MAA) are modified in the Qatar Reference Genome (QTRG).

# **Figure Legends**

**Figure 1.** Differences in mapped read depth across reference genomes. In order to select the optimal reference for analysis of Qatari genomes and exomes, the mapped read depth was compared between GRCh37 and three alternative reference genomes based on major alternate alleles (MAA) observed in n=1005 Qatari. Illumina paired-end 100 bp reads for 37\* genome sequencing of a female Qatari were mapped using BWA to GRCh37, QTRG1, QTRG2, and QTRG3 reference genomes. The differences between the three Qatari references is that QTRG1 incorporates MAA SNPs, QTRG2 incorporates MAA indels, and QTRG3 incorporates both MAA SNPs and MAA indels. The depth of coverage was measured at **A.** across the genome and **B.** at MAA sites modified in the QTRG.

# A. Modified sites





#### **Supplemental Methods**

## **Inclusion Criteria**

In order to maximize the accuracy of Qatari ancestry inference, both Qataris and non-Qatari Non-Qataris living in Qatar were selected for sequencing. As selection criteria for Qataris, subjects were required to be third generation Qataris where all four grandparents were Qatari citizens born in Qatar, as assessed by questionnaires. Recent immigrants or residents of Qatar who traced their recent ancestry to other geographic regions were classified as Non-Qataris. DNA was extracted from blood using the QIAamp DNA Blood Maxi Kit (Qiagen Sciences Inc., Germantown, MD).

DNA samples were collected for a total of 1,376 unique individuals. Samples included in this study were obtained from two separate studies, the first being a study of diabetes in unrelated Qataris (1,084), and the second being a study of Mendelian disorders in Qatari and Non-Qatari families living in Qatar (292).

## **Ancestry Informative Marker Panel Genotyping**

An initial estimate of the ancestry of each Qatari was conducted on all 3-generation Qataris. Based on prior studies of Affymetrix  $5.0^{1,2}$  and exome sequencing<sup>1,3,4</sup> of Qataris, most Qataris can be placed into one of three ancestry subpopulations: Bedouin (Q1), Persian/South Asian (Q2) and African (Q3)<sup>1,4</sup>. An estimate of the relative proportions of tripartite ancestry was also estimated in each Qatari based on genotypes for a panel of 48 ancestry-informative SNPs<sup>4</sup> ascertained using the TaqMan platform (Life Technologies, Carlsbad, CA), followed by STRUCTURE<sup>5</sup> analysis with k=3, where individuals with at least 65% ancestry in one of three clusters were classified as "low admixture" Qataris. Qataris were recruited for genetic studies at Hamad Medical Corporation clinics, and consenting volunteers were initially genotyped on the 48-SNP ancestry panel. Individuals with a high proportion of ancestry in one of three clusters were prioritized for sequencing. DNA was extracted from blood using the QIAamp DNA Blood Maxi Kit (Qiagen Sciences, Germantown, MD).

## **Genome Sequencing**

In order to characterize the spectrum of Qatari genetic variation, 108 Qataris were sequenced to a median depth of 37x on the Illumina platform. Next-generation sequencing libraries were generated using the Illumina TruSeq protocol, and sequencing was conducted at the Illumina FastTrack Services sequencing facility using the HiSeq 2500<sup>6</sup>. Sufficient paired-end 100 bp reads were generated in order to produce a median of 112 GB of sequence data passing filters and aligned to the hg19 human reference genome with a median insert size of 301 bp, where at least 85% of bases  $\geq$ Q30, passed filtering steps and were aligned. Among non-N bases in the reference genome, at least 98% were covered by at least one base in all 108 genomes. Reads were realigned to the 1000 Genomes Project version of the GRCh37 human reference genome using BWA 0.5.9<sup>7</sup> (maximum insert size 3 kb), and mapped reads were prepared for variant calling using GATK Best Practices<sup>8</sup>, including PCR duplicate removal using SAMtools<sup>9</sup>, producing an average of 37x depth in autosomal chromosomes, with a mean of 98% of mappable sites covered per genome. SNP genotypes for all 108 genomes were simultaneously called using GATK<sup>10</sup>. In addition, short indel (<300 bp) calls were produced using the CASAVA 1.9 pipeline by Illumina.

## **Exome Sequencing**

Exome sequence data was produced for 1,268 Qataris. In addition, 53 technical replicates were produced, a total of 1,321 exomes sequenced and analyzed, where the entire sample included 1,053 unique Qataris and 215 unique Non-Qataris. A total of 1,221 exomes were sequenced by the New York Genome Center (NYGC), an additional 100 Qatari were sequenced at Beijing Genomics Institute (BGI)<sup>4</sup>. The NYGC exomes were produced using Agilent SureSelect Human All Exome 51 Mb targets, and are hearafter referred to as "Exome51Mb", while the BGI

exomes were produced using Agilent SureSelect Human All Exome 38 Mb targets, hereafter referred to as "Exome38Mb".

The Exome51Mb batch was produced using standard methods. Exome DNA enrichment was performed using Agilent SureSelect Human All Exon Kit V5 (Agilent Technologies, Santa Clara, CA) hybrid capture targets for 51 Mb of coding regions, with sequencing on the Illumina HiSeq 2500 platform<sup>6</sup>. Reads were mapped to GRCh37 using BWA v0.5.9<sup>7</sup>, mean coverage depth was verified to be greater than 30x for all autosomal chromosomes in all samples. Quality filtering of mapped reads was conducted using the GATK Best Practices workflow<sup>8</sup>, including realignment across known indels, recalibration of base quality scores, and removal of duplicate reads.

### **Technical Replicates**

Technical replicates in the study included 5 sequenced in triplicate (genome, Exome38Mb, Exome51Mb) and 43 that were sequenced on two platforms, including 26 genome and Exome38Mb (31 total, including the 5 triplicates), 4 sequenced genomes Exome51Mb (9 total, including the 5 triplicates), 2 sequenced in both Exome51Mb and Exome38Mb batches (7 total), and 11 sequenced twice in the Exome51Mb batch. The genotypes for these technical replicates were compared to assess overall reproducibility across sequencing platforms. The genome of the triplicate (a Qatari female) was subsequently sequenced on a fourth platform (Illumina HiSeq X), in order to have one quadruple-sequenced Qatari to use as a benchmark for analysis.

## **Integrated Analysis of Exome and Genome Samples**

In order to conduct analysis of population structure and relatedness on the maximum number of samples, genotype data from the 108 genomes was integrated with exome sequence data for 1,268 Qataris. Including the technical replicates, a call set for all 1,429 samples was produced by simultaneous genotyping using the GATK UnifiedGenotyper algorithm<sup>10</sup>. Genotype-

ready BAM alignment files were prepared as described above for genome, Exome51Mb, and Exome38Mb samples. Genotype calling was limited to sites in the Agilent SureSelect 38Mb targets that overlap CCDS build 15 coding exons<sup>11</sup>. Variants observed in at least one sample with Q30 or higher were reported. All bi-allelic SNPs genotyped successfully in at least 80% of samples were kept for further analysis. In order to facilitate downstream analysis, variant VCF files were converted to PLINK<sup>12</sup> format using PLINK2<sup>13</sup>.

## **Optimization of Batch-Specific Genotype Filters**

Integration of data from three distinct batches of sequence data produced at three distinct sequencing centers on three distinct sequencing library preparation kits and three different versions of the Illumina sequencer introduces a number of variables that could potentially result inbatch effects in the variant calls. Novel variants, defined as those not present in dbSNP (build 146 being the latest at the time of writing), singletons (single alleles observed in only one individual in the population sample), and genotypes with low sequencing depth are typically enriched for sequencing errors and batch artifacts<sup>14</sup>. Hence, one way to control for batch effects is to filter variants below a threshold depth d and threshold variant allele count v, such that the mean novel SNP rate is consistent across batches within genomic intervals covered by the intersection of all batches. In order to optimize d and v, two approaches were followed. First, the novel SNP rate for a range of d and v thresholds were calculated in each batch, and batch-specific d and v that produced the highest possible consistent novel SNP rate was selected and applied to each call set. Second, the impact of the selected batch-specific filters d and v were applied to the quadruple-sequenced Qatari, and the proportion of batch-specific variants (defined as variants observed in only one of the four batches in the quadruple-sequenced Qatari) was compared before and after application of filters. The proportion of batch-specific variants was calculated for both all variants and novel variants, with the aim of controlling the batch-specific variants at below 5%.

A major concern when applying genotype filters is the risk of reducing sensitivity for known and novel variants. In order to confirm that overly-stringent filtering was applied, the impact of the selected filters on sensitivity and novel SNP rate was assessed across a range of depths for the quadruple-sequenced Qatari, in order to ensure that the number of variants observed within CCDS coding exons (within the Exome38Mb target intervals) was in the range of published benchmarks of per-exome variant counts<sup>15</sup>, and that excess novel SNP rates were avoided.

### **Population Structure**

In order to quantify admixture in 1,161 Qataris and 215 Non-Qataris living in Qatar, the integrated SNP genotypes of 1376 individuals within Agilent SureSelect 38 Mb targets were integrated with 4,235 genomes from public databases. The public databases included 1,862 from Human Origins (HumOr), 1,028 from 1000 Genomes Phase 1 not in HumOr (1000Gp1), and 1,345 from 1000 Genomes Phase 3 not in HumOr nor 1000Gp1 (1000Gp3). The integrated variant dataset included 5,611 SNPs segregating in all datasets (Qatar Genomes, Qatar Exomes, HumOr, 1000Gp1, 1000Gp3) after filtering to exclude SNPs with more than 20% missing genotypes, SNPs with Hardy Weinberg equilibrium pruning (conducted using PLINK2), and SNPs removed by linkage disequilibrium pruning (conducted using the PLINK2 –indeppairwise function in a sliding window of 1000 SNPs, step size 25 SNPs, and exclusion of SNPs with  $r^2 > 0.1$ ). Inference of ancestry was conducted using ADMIXTURE<sup>16</sup> for the 5,611 individuals. Ancestry proportion inference was conducted using K=12, based on lowest cross-validation error in a prior study<sup>17</sup>. For each individual, ADMIXTURE outputs the proportion of ancestry in each ancestral population (K). Each individual was assigned to the ancestral population with the

largest proportion in his or her genome.

## Relatedness

Given the high rate of consanguineous marriage in Qatar<sup>18</sup>, and the inclusion of complete families in our study, the potential over-sampling of relatives and families in sample of the population is high. In order to avoid over-sampling or alleles from relatives, and produce allele frequency estimates for the general Qatari population, the pairwise relatedness between 1,376 samples (including Qataris and Non-Qataris living in Qatar, after exclusion of technical replicates) was calculated using KING<sup>19</sup>, and 1<sup>st</sup>/2<sup>nd</sup> degree relatives were excluded. Genotypes used for comparison were limited to CCDS coding intervals covered in the intersection of the three sequencing batches (n=108 genome, n=67 Exome38Mb, and n=1201 Exome51Mb). Given the high level of inbreeding in the Qatari population<sup>18</sup>, and the use of coding variant data for the analysis, the pairwise relatedness estimates of KING and related software are expected to over-estimate relatedness<sup>19-21</sup>, such that assessment of 1<sup>st</sup>/2<sup>nd</sup> degree relatedness is expected to be a liberal and therefore over-assessment of relatedness in the sample. Using this liberal cutoff, a total of 1005 unrelated Qataris (n=88 genome, n=64 Exome38Mb, and n=853 Exome51Mb) were identified, resulting in the exclusion of 156 1<sup>st</sup>/2<sup>nd</sup> degree Qatari relatives.

#### **Construction of the Qatari Reference Genome (QTRG)**

Total variants were counted in each chromosome of the n=88 unrelated Qatari genomes and n=917 unrelated Qatari exomes, and an aggregate variant list was compiled. Variant allele frequency was calculated using PLINK2<sup>12</sup> and VCFtools<sup>22</sup>. Novel variants (defined as not present in dbSNP build 146) were quantified in both individual and aggregate sets, as was the Ts:tv ratio (measured using VCFtools<sup>22</sup>).Variants in Qatar were divided into 2 categories based on which allele is the major allele, subsequently described as major reference alleles (MRA) and major alternate alleles (MAA) Three versions of the Qatar Reference Genome were produced. In order to produce an initial version of the Qatari Reference Genome (referred to as "QTRG1"), the standard reference genome (GRCh37) was modified at all sites where the variant allele in Qatar is the major allele in Qatar, in this case including all MAA SNPs. The modifications to the GRCh37 FASTA<sup>23</sup> file was conducted using VCFtools<sup>22</sup>, which takes the reference genome and a VCF file with the major allele variants as inputs, and outputs a modified FASTA file. QTRG1 was prepared for use in analysis of human genomes and exomes by creation of indexed versions of the reference using SAMtools<sup>9</sup>, Picard<sup>7,24</sup>, and BWA<sup>7</sup>. A second version of the Qatar Reference Genome (QTRG2) was produced by including all MAA indels. A third version of the Qatar Reference Genome (QTRG3) was produced by including the MAA SNPs and MAA indels.

## Assessment of QTRG vs GRCh37 on "n+1" Qatari

The value of the QTR1 population-specific reference genome for assessing major and minor allele variants was demonstrated by genome interpretation of the next Qatari sequenced, referred to the "n+1" genome, defined as the "next" genome sequenced and analyzed using data from the panel of n=1005 genomes analyzed thus far. The n+1 analysis was conducted by taking the sequence data for an individual genome, and processing it twice using the same GATK Best Practices Workflow<sup>8</sup>, with the only difference being the reference genome used. Three experiments were conducted in order to assess the value of using QTRG. First, genome sequence data for the quadruple-sequenced Qatari was mapped to four references (including GRCh37, QTRG1, QTRG2, and QTRG3), and differences in mapped read depth at both modified and unmodified sites was compared. The reference with the greatest mapped read depth (in this case QTRG3) was selected for the two other experiments. Second, a family of 15 genomes sequenced at 37x depth using paired-end Illumina 100bp sequencing was analyzed using the GATK Best Practices Workflow<sup>8</sup> twice, with the only change being the reference genome used (GRCh37 or QTRG3). The depth and number of variants was compared between the two references for each individual. In addition, in order to assess the impact of using the reference beyond modified sites, the observed reduction in number of variants was compared to the expected number, where the expected reduction is the number of number of "flipped" variants (variants incorporated into the QTRG3 reference) present in the individual genome. The difference across the 15 genomes was tested for significance using a 2-df Chi-squared test. Third, the analysis was repeated on a diverse panel of n=16 Qatari exomes, and differences in the increased depth and reduced variant count was compared across populations with a one-tailed t-test.

### **Gene and Variant Annotation Liftover**

A major issue for utilizing the QTRG3 reference genome in n+1 genome interpretation is the need to update the positions of known genes and variants. In genomics this is known as a "liftover", an analysis that is conducted each time a new version of the human reference genome assembly is produced. In order to assess the feasibility QTRG3 for genome interpretation, a liftover analysis was conducted for known pathogenic variants observed in filtered call set for the n=1005 unrelated Qatari. The variants with respect to GRCh37 were annotated, and then the variant coordinates were "lifted over" to QTRG3 coordinates. The liftover process has two steps, first each chromosome of GRCh37 and QTRG3 are pairwise aligned using ProgressiveCactus<sup>25</sup>. Then, using the pairwise global alignment of the two chromosomes, a list GRCh37 coordinates are converted to QTRG3 coordinates using HalTools<sup>26</sup> Given that the SNPs lifted over are present in dbSNP, the liftover success could be assessed using the dbSNP flanking sequenced for each SNP, which can be aligned to QTRG3 in order to identify a precise location using MUMer<sup>27</sup>.

#### Variant Functional Interpretation

Functional interpretation was conducted for the 26 million SNPs and indels identified in

Qatar using a combination of automated and manual algorithms. The automated curation consisted of identifying potentially deleterious coding variants, annotation and subdivision of the potentially deleterious variants based on presence or absence of the variants and/or affected genes in databases of variants and genes previously linked to phenotypes, followed by further subdivision based on variant allele frequency in Qatar.

Variants were assigned to genes in the ENSEMBL database build 75<sup>28</sup> using SnpEff  $4.1^{29}$ . In cases where multiple alternative transcripts overlap with distinct potential functions, the most severely deleterious function was reported, based on a prioritization hierarchy described in the annotation tool manual<sup>29</sup>. SnpEff classifies variant (SNP and indel) impact into three categories "high", "moderate", "low", or "modifier", where loss of function (LoF) variants are classified as high impact, nonsynonymous variants are classified as moderate impact, the remaining coding variants are classified as low impact, and most non-coding variants are classified as modifier impact. The high impact and moderate impact variants are considered potentially deleterious, and further classified with respect to databases of variant function and allele frequency. A known or potential link to a phenotype was determined using a database that combines Online Mendelian Inheritance in Man (OMIM)<sup>30</sup>, the Human Gene Mutation Database (HGMD)<sup>31</sup>, GWAS Catalog (GWAS)<sup>32</sup>, and Pharmacogenomics Knowledgebase (PharmGKB)<sup>32,33</sup>, Clin-Var<sup>34</sup>, and Human Phenotype Ontology (HPO)<sup>35</sup>. While the HGMD, GWAS, PharmGKB, and ClinVar databases provide annotation for variants, the OMIM database also provides information for genes and phenotypes, and HPO provides additional detail on the OMIM phenotypes (such as recessive/dominant classification). Qatari variants linked to a phenotype in the combined database of genes and variants linked to disease were identified based on the gene symbol containing the variant or the dbSNP rsID of the variant. The workflow for automated annotation starts with a VCF of all variants observed in the n=88 unrelated Qatari genomes or n=917 unrelated Qatari

exomes. Each variant is assigned a function by SnpEff, with additional details provided for coding SNPs, such as transcript and polypeptide position and amino acid changes in HGVS format<sup>36</sup>. The variants were also assigned dbSNP 146 rsIDs, which were used to lookup the variant in the databases.

Potentially deleterious variants (high or moderate impact) are then queried against a database of variants linked to disease. The database includes the rsID, affected gene, phenotype linked to the variant, details of the phenotype, MIM ID of the gene and phenotype if available, and reference to the source database. This query produces the first group of variants (Category 1), where the variant (and the gene) are previously linked to a phenotype in one or more of the databases. The variants not present in the database are then queried against a list of all genes in the database, in order to produce the second group of variants (Category 2), variants not previously linked to a phenotype in genes previously linked to a phenotype. The remaining variants were placed a third group (Category 3), consisting of variants not linked to a phenotype in genes not previously linked to a phenotype.

The functional analysis was further stratified based on allele frequency. Each of the four categories of variants (all, Category 1, Category 2, Category 3) were stratified into 3 major groups (all, major reference allele, major alternate allele), and 5 minor groups (major reference allele / rare alternate allele, major reference allele / common alternate allele, major alternate allele, frare alternate allele, major alternate allele / rare reference allele, major alternate allele / unobserved reference allele), where the threshold for "rare" alleles is 5% minor allele frequency.

#### Curated List of Known Pathogenic Variants for Mendelian Disorders in Qatar

The set of Category 1 variants were filtered using a set of strict automated and manual

curation steps, in order to produce a list of potential disease causing variants of interest for further study and potentially of value for an expanded genetic screening panel in Qatar<sup>4</sup>. The total set of potentially deleterious variants were filtered based on prevalence of the variant as well as the quality of literature linking the variant to a disease phenotype. The American College of Medical Genetics (ACMG) recommends excluding variants at prevalence above 5% minor allele frequency, in order to enrich for pathogenic variants<sup>37</sup>. Such a filter is consistent with a basic principle of evolutionary biology states that the prevalence of an allele in the population is expected to be inversely proportional to its pathogenic severity<sup>38</sup>, with the most severely pathogenic variants expected to be rare. In addition, in order to minimize false positives, variants that were observed in at least two Qataris were keep for further consideration.

The Category 1 variants include all variants linked to a phenotype, including anthropomorphic traits (eye, hair color), GWAS hits, pharmacogenomics SNPs, and variants linked to Mendelian disorders, across the allele frequency spectrum. For the purpose of improving precision medicine in Qatar with respect to Mendelian disease variant screening, the focus of manual curation was on variants linked to Mendelian disorders. In order to identify a high-confidence set of known pathogenic variants, the database records and literature of the initial set of Category 1 variants linked to phenotypes were manually inspected. The initial criteria for extracting variants for manual curation were based on the phenotype (Mendelian or not). Variants were excluded from the manual curation list based on phenotype not listed as "recessive" or "dominant" Mendelian disorder in OMIM<sup>30</sup> and HPO<sup>39</sup>. For the remaining variants, a manual curation process was implemented to identify a subset of high-confidence pathogenic variants for precision medicine disease screening in Qatar. First, the entry for each variant on the OMIM webpage was evaluated to determine the strength of evidence supporting this variant's pathogenicity in the reported disease. For this step, the entry was scrutinized by a geneticist blinded to variant-specific metrics (observed homozygotes/heterozygotes), in each instance reporting inheritance mode of the disease documented for this variant (as RECESSIVE, DOMINANT, SEMIDOMINANT, DIGENIC or MODIFIER) along with relevant severity and onset information (as MILD, LATE-ONSET, INCOMPLETE/REDUCED PENTRANCE, or PHARMACOGENETIC). Where any of this information was missing from the OMIM page, the primary literature was investigated in detail by reviewing the initial publication in which the subject with disease was initially described, as well as any subsequent publication that supported or overturned the pathogenicity. The final criteria for exclusion was variants associated with but not causal for a disease (conferring odds of risk of disease), pharmacogenetic variants (requiring a challenge by a drug for a phenotype), or variants that were reclassified in more recent studies as polymorphisms or variants of unknown significance.
Nickname	Geno	me	Exome 3	38 Mb	Exome 51 Mb		
Sequencing breadth	Whole g	enome	Whole e	exome	Whole exome		
Sequencing year	201	2	201	0	2014		
Enrichment platform	N/A	A	SureSelec	t 38 Mb	SureSelect 51 Mb		
Sequencing platform	Illumina Hi	Seq 2500	Illumina Hi	Seq 2000	Illumina HiSeq 2500		
Sample size	108	3	67		120	1	
Filters							
Minimum depth	12		12	,	10		
Minimum allele count	1		1		2		
Mean depth	38		70		70		
Novel variants (% not in dbSNP 146)	0.73	%	0.72	%	0.72%		
Autosomal variant summary	All	Novel	All	Novel	All	Novel	
Variant alleles	19,355	104	18,537	100	19,229	103	
Variant sites	14,107	103	13,682	98	14,064	102	
Reference homozygotes	287,672	62,601	268,401	58,600	161,239	19,421	
Heterozygotes	8,860	102	8,826	97	8,898	101	
Variant homozygotes	5,247	1	4,856	1	5,166	1	
Homozygotes	292,919	62,603	273,257 58,602		166,405	19,422	

Supplemental Table I. Batch-specific variant filters for call set integration of 108 genomes and 1268 exomes <sup>1</sup>

<sup>1</sup> In order to produce an integrated variant call set based on sequence data from three different batches (1 genome, 2 exome), batch-specific variant filters were applied, such that the novel SNP rate was consistent across platforms when inspecting genomic intervals covered by all platforms. Genotypes generated using GATK best practices were produced for autosomal coding exons covered by Agilent SureSelect 38 Mb targets, the most restricted platform used (with respect to breadth of genome sampled), and further limited to known coding exons present in the CCDS database (which is an intersection of RefSeq, ENSEMBL, and UCSC defined genes). From the initial call set, sites with a PHRED-scaled genotype quality above 30 were further filtered using a range of minimum depth and minimum allele count, and compared with respect to novel SNP rate (defined as the percentage of variant sites not previously observed in dbSNP build 146). The combinations were sorted by increasing novel SNP rate, and batch-specific parameters were selected such that (a) both exome platform novel SNP rates are lower than the genome novel SNP rate, the genome novel SNP rate is as close as possible to the exome novel SNP rate, and the lowest SNP rate is as high as possible. Based on analysis of a quadruple-sequenced Qatari, the batch-specific novel variant rate for these parameters is below 5%. Shown are the sequencing parameters, calibration parameters, and autosomal variant summary for each platform. Sequencing parameters include a name for each platform. The Calibration parameters include the minimum depth, minimum allele count, mean variant depth, and percentage of novel variants (not in dbSNP 146) for the selected optimal batch-specific filters. The autosomal variant summary presents for all and for novel SNPs the average result per individual for the selected calibration parameters, including number of variant alleles, variant sites, reference homozygous genotypes, heterozygous genotypes, variant homozygous genotypes.

Study	Region	Population	n
1000Gp1	AFR	ASW	61
1000Gp1	AFR	LWK	95
1000Gp1	AFR	YRI	57
1000Gp1	AMR	CLM	60
1000Gp1	AMR	MXL	66
1000Gp1	AMR	PUR	55
1000Gp1	EAS	CHB	97
1000Gp1	EAS	CHS	100
1000Gp1	EAS	JPT	89
1000Gp1	EUR	CEU	85
1000Gp1	EUR	FIN	86
1000Gp1	EUR	GBR	76
1000Gp1	EUR	IBS	3
1000Gp1	EUR	TSI	98
1000Gp3	AMR	ACB	96
1000Gp3	AMR	ASW	7
1000Gp3	AMR	CLM	36
1000Gp3	AMR	MXL	5
1000Gp3	AMR	PEL	85
1000Gp3	AMR	PUR	49
1000Gp3	EASN	CDX	93
1000Gp3	EASN	CHB	8
1000Gp3	EASN	CHS	13
1000Gp3	EASN	JPT	15
1000Gp3	EASN	KHV	91
1000Gp3	EUR	CEU	15
1000Gp3	EUR	FIN	10
1000Gp3	EUR	GBR	9
1000Gp3	EUR	IBS	44
1000Gp3	EUR	TSI	11
1000Gp3	SASN	BEB	79
1000Gp3	SASN	GIH	86
1000Gp3	SASN	ITU	102
1000Gp3	SASN	PJL	88
1000Gp3	SASN	STU	102
1000Gp3	WAFR	ESN	91
1000Gp3	WAFR	GWD	107
1000Gp3	WAFR	LWK	12
1000Gp3	WAFR	MSL	78
1000Gp3	WAFR	YRI	13
Non-Qatari in Qatar Exome	Africa	Algerian	1
Non-Qatari in Qatar Exome	Africa	American/Egyptian	5
Non-Qatari in Qatar Exome	Africa	Egyptian	41
Non-Qatari in Qatar Exome	Africa	Eritrean	4

Supplemental Table II. Populations included in ADMIXTURE and PCA analysis  $^{\rm 1}$ 

# Supplemental Table II. Populations included in ADMIXTURE and PCA analysis<sup>1</sup> (cont., page 2)

Study	Region	Population	n
Non-Qatari in Qatar Exome	Africa	Morracan	1
Non-Qatari in Qatar Exome	Africa	Nigerian	2
Non-Qatari in Qatar Exome	America	American	5
Non-Qatari in Qatar Exome	America	Argentenian	1
Non-Qatari in Qatar Exome	East Asia	Filipino	3
Non-Qatari in Qatar Exome	East Asia	Nepalese	1
Non-Qatari in Qatar Exome	Middle East	Arab	1
Non-Qatari in Qatar Exome	Middle East	Iranian	10
Non-Qatari in Qatar Exome	Middle East	Iraqi	1
Non-Qatari in Qatar Exome	Middle East	Jordanian	21
Non-Qatari in Qatar Exome	Middle East	Jordanian/Arab	3
Non-Qatari in Qatar Exome	Middle East	Jordanian/Palestinian	1
Non-Qatari in Qatar Exome	Middle East	Lebanese	4
Non-Qatari in Qatar Exome	Middle East	Omani	8
Non-Qatari in Qatar Exome	Middle East	Palestinian	20
Non-Qatari in Qatar Exome	Middle East	Saudi	3
Non-Qatari in Qatar Exome	Middle East	Sri-Lankan	1
Non-Qatari in Qatar Exome	Middle East	Sudanese	16
Non-Qatari in Qatar Exome	Middle East	Syrian	9
Non-Qatari in Qatar Exome	Middle East	Tunisian	5
Non-Qatari in Qatar Exome	Middle East	Yemeni	5
Non-Qatari in Qatar Exome	South Asia	Bangladeshi	2
Non-Qatari in Qatar Exome	South Asia	Indian	10
Non-Qatari in Qatar Exome	South Asia	Indian/Asian	5
Non-Qatari in Qatar Exome	South Asia	Pakistani	26
Human Origins	Africa	AA Denver	12
Human Origins	Africa	Algerian	7
Human Origins	Africa	Bantu SA Herero	2
Human Origins	Africa	Bantu SA Ovambo	1
Human Origins	Africa	Bantu SA Pedi	1
Human Origins	Africa	Bantu SA S Sotho	1
Human Origins	Africa	Bantu SA Tswana	2
Human Origins	Africa	Bantu SA Zulu	1
Human Origins	Africa	BantuKenya	6
Human Origins	Africa	BiakaPygmy	20
Human Origins	Africa	Datog	3
Human Origins	Africa	Esan Nigeria ESN	8
Human Origins	Africa	Gambian GWD	6
Human Origins	Africa	Hadza Henn	5
Human Origins	Africa	Ju hoan North	5
Human Origins	Africa	Khomani	11
Human Origins	Africa	Kikuyu	4
Human Origins	Africa	Luhya Kenya LWK	8
Human Origins	Africa	Luo	8
Human Origins	Africa	Mandenka	17

# Supplemental Table II. Populations included in ADMIXTURE and PCA analysis<sup>1</sup> (cont., page 3)

Study	Region	Population	n
Human Origins	Africa	Masai Ayodo	2
Human Origins	Africa	Masai Kinyawa MKK	10
Human Origins	Africa	MbutiPygmy	10
Human Origins	Africa	Mende Sierra Leone MSL	8
Human Origins	Africa	Mozabite	21
Human Origins	Africa	Saharawi	6
Human Origins	Africa	Somali	13
Human Origins	Africa	Tunisian	8
Human Origins	Africa	Yoruba	70
Human Origins	America	Bolivian Cochabamba	1
Human Origins	America	Bolivian LaPaz	3
Human Origins	America	Bolivian Pando	3
Human Origins	America	Karitiana	12
Human Origins	America	Mayan	18
Human Origins	America	Mixe	10
Human Origins	America	Mixtec	10
Human Origins	America	Ріаросо	4
Human Origins	America	Pima	14
Human Origins	America	Quechua Coriell	5
Human Origins	America	Surui	8
Human Origins	America	Zapotec	10
Human Origins	Central Asia Siberia	Aleut	7
Human Origins	Central Asia Siberia	Altaian	7
Human Origins	Central Asia Siberia	Chukchi	20
Human Origins	Central Asia Siberia	Chukchi Reindeer	1
Human Origins	Central Asia Siberia	Chukchi Sir	2
Human Origins	Central Asia Siberia	Dolgan	3
Human Origins	Central Asia Siberia	Eskimo Chaplin	4
Human Origins	Central Asia Siberia	Eskimo Naukan	13
Human Origins	Central Asia Siberia	Eskimo Sireniki	5
Human Origins	Central Asia Siberia	Even	10
Human Origins	Central Asia Siberia	Itelmen	6
Human Origins	Central Asia Siberia	Kalmyk	10
Human Origins	Central Asia Siberia	Koryak	9
Human Origins	Central Asia Siberia	Kyrgyz	9
Human Origins	Central Asia Siberia	Mansi	8
Human Origins	Central Asia Siberia	Mongola	6
Human Origins	Central Asia Siberia	Nganasan	11
Human Origins	Central Asia Siberia	Selkup	10
Human Origins	Central Asia Siberia	Tajik Pomiri	8
Human Origins	Central Asia Siberia	Tlingit	4
Human Origins	Central Asia Siberia	Tubalar	22
Human Origins	Central Asia Siberia	Turkmen	7
Human Origins	Central Asia Siberia	Tuvinian	10
Human Origins	Central Asia Siberia	Ulchi	25

# Supplemental Table II. Populations included in ADMIXTURE and PCA analysis<sup>1</sup> (cont., page 4)

Study	Region	Population	n
Human Origins	Central Asia Siberia	Uzbek	10
Human Origins	Central Asia Siberia	Yakut	20
Human Origins	Central Asia Siberia	Yukagir Forest	5
Human Origins	Central Asia Siberia	Yukagir Tundra	14
Human Origins	East Asia	Ami Coriell	10
Human Origins	East Asia	Atayal Coriell	9
Human Origins	East Asia	Cambodian	8
Human Origins	East Asia	Dai	10
Human Origins	East Asia	Daur	9
Human Origins	East Asia	Han	33
Human Origins	East Asia	Han NChina	10
Human Origins	East Asia	Hezhen	8
Human Origins	East Asia	Japanese	29
Human Origins	East Asia	Kinh Vietnam KHV	8
Human Origins	East Asia	Korean	6
Human Origins	East Asia	Lahu	8
Human Origins	East Asia	Miao	10
Human Origins	East Asia	Naxi	9
Human Origins	East Asia	Orogen	9
Human Origins	East Asia	She	10
Human Origins	East Asia	Thai	10
Human Origins	East Asia	Tu	10
Human Origins	East Asia	Tujia	10
Human Origins	East Asia	Uygur	10
Human Origins	East Asia	Xibo	7
Human Origins	East Asia	Yi	10
Human Origins	Middle East	BedouinA	25
Human Origins	Middle East	BedouinB	19
Human Origins	Middle East	Druze	39
Human Origins	Middle East	Egyptian Comas	11
Human Origins	Middle East	Egyptian Metspalu	7
Human Origins	Middle East	Iranian	8
Human Origins	Middle East	Jordanian	9
Human Origins	Middle East	Lebanese	8
Human Origins	Middle East	Palestinian	38
Human Origins	Middle East	Saudi	8
Human Origins	Middle East	Syrian	8
Human Origins	Middle East	Turkish	4
Human Origins	Middle East	Turkish Adana	10
Human Origins	Middle East	Turkish Aydin	7
Human Origins	Middle East	Turkish Balikesir	6
Human Origins	Middle East	Turkish Istanbul	10
Human Origins	Middle East	Turkish Kayseri	10
Human Origins	Middle East	Turkish Trabzon	9
Human Origins	Middle East	Yemen	6

# Supplemental Table II. Populations included in ADMIXTURE and PCA analysis<sup>1</sup> (cont., page 5)

Study	Region	Population	n
Human Origins	Oceania	Australian ECCAC	3
Human Origins	Oceania	Bougainville	10
Human Origins	Oceania	Papuan	14
Human Origins	South Asia	Balochi	20
Human Origins	South Asia	Bengali Bangladesh BEB	7
Human Origins	South Asia	Brahui	21
Human Origins	South Asia	Burusho	23
Human Origins	South Asia	GujaratiA GIH	5
Human Origins	South Asia	GujaratiB GIH	5
Human Origins	South Asia	GujaratiC GIH	5
Human Origins	South Asia	GujaratiD GIH	5
Human Origins	South Asia	Hazara	14
Human Origins	South Asia	Kalash	18
Human Origins	South Asia	Kusunda	10
Human Origins	South Asia	Makrani	20
Human Origins	South Asia	Pathan	19
Human Origins	South Asia	Punjabi Lahore PJL	8
Human Origins	South Asia	Sindhi	18
Human Origins	West Eurasia	Abkhasian	9
Human Origins	West Eurasia	Adygei	17
Human Origins	West Eurasia	Albanian	6
Human Origins	West Eurasia	Armenian	10
Human Origins	West Eurasia	Balkar	10
Human Origins	West Eurasia	Basque French	20
Human Origins	West Eurasia	Basque Spanish	9
Human Origins	West Eurasia	Belarusian	10
Human Origins	West Eurasia	Bulgarian	10
Human Origins	West Eurasia	Chechen	9
Human Origins	West Eurasia	Chuvash	10
Human Origins	West Eurasia	Croatian	10
Human Origins	West Eurasia	Cypriot	8
Human Origins	West Eurasia	Czech	10
Human Origins	West Eurasia	English Cornwall GBR	5
Human Origins	West Eurasia	English Kent GBR	5
Human Origins	West Eurasia	Estonian	10
Human Origins	West Eurasia	Finnish FIN	7
Human Origins	West Eurasia	French	25
Human Origins	West Eurasia	French South	7
Human Origins	West Eurasia	Georgian Megrels	10
Human Origins	West Eurasia	Greek Comas	14
Human Origins	West Eurasia	Greek Coriell	6
Human Origins	West Eurasia	Hungarian Coriell	10
Human Origins	West Eurasia	Hungarian Metspalu	10
Human Origins	West Eurasia	Icelandic	12
Human Origins	West Eurasia	Italian Bergamo	12

#### Supplemental Table II. Populations included in ADMIXTURE and PCA analysis<sup>1</sup> (cont., page 6)

Study	Region	Population	n
Human Origins	West Eurasia	Italian EastSicilian	5
Human Origins	West Eurasia	Italian South	1
Human Origins	West Eurasia	Italian Tuscan	8
Human Origins	West Eurasia	Italian WestSicilian	6
Human Origins	West Eurasia	Kumyk	8
Human Origins	West Eurasia	Lezgin	9
Human Origins	West Eurasia	Lithuanian	10
Human Origins	West Eurasia	Maltese	8
Human Origins	West Eurasia	Mordovian	10
Human Origins	West Eurasia	Nogai	9
Human Origins	West Eurasia	North Ossetian	10
Human Origins	West Eurasia	Norwegian	11
Human Origins	West Eurasia	Orcadian	13
Human Origins	West Eurasia	Russian	22
Human Origins	West Eurasia	Saami WGA	1
Human Origins	West Eurasia	Sardinian	27
Human Origins	West Eurasia	Scottish Argyll Bute GBR	4
Human Origins	West Eurasia	Spanish Andalucia IBS	4
Human Origins	West Eurasia	Spanish Aragon IBS	6
Human Origins	West Eurasia	Spanish Baleares IBS	4
Human Origins	West Eurasia	Spanish Canarias IBS	2
Human Origins	West Eurasia	Spanish Cantabria IBS	5
Human Origins	West Eurasia	Spanish Castilla la Mancha IBS	5
Human Origins	West Eurasia	Spanish Castilla y Leon IBS	5
Human Origins	West Eurasia	Spanish Cataluna IBS	5
Human Origins	West Eurasia	Spanish Extremadura IBS	5
Human Origins	West Eurasia	Spanish Galicia IBS	5
Human Origins	West Eurasia	Spanish Murcia IBS	4
Human Origins	West Eurasia	Spanish Pais Vasco IBS	5
Human Origins	West Eurasia	Spanish Valencia IBS	5
Human Origins	West Eurasia	Ukrainian East	6
Human Origins	West Eurasia	Ukrainian West	3
Qatar Exome	Qatar	Qatari	108
Qatar Genome	Qatar	Qatari	1268

<sup>1</sup> Shown is the sample size in the dataset used for population structure analysis, including samples from 1000 Genomes Phase 1<sup>40</sup> (1000Gp1), 1000 Genomes Phase 3<sup>41</sup> (1000Gp3), Human Origins (HumOr), Qatar Genome (QG), Qatar Exome (QE), and Non-Qataris in Qatar Exome (NQE). A number of samples overlap between HumOr, 1000Gp1, and 1000Gp3, in these cases firs the HumOr samples are added, followed by non-duplicate samples in 1000Gp3, and finally non-duplicate samples in 1000Gp3. In order to distinguish between 1000G and HumOr samples for the same populations, the 1000 Genomes populations are described by a 3-letter code (such as YRI), while HumOr samples use the full name (such as Yoruba) in Lazardis et al 2014 supplement<sup>42</sup>. Shown is the study, region, population, and sample size. For Qataris, the sample size is based the sequencing technology used (genome or exome). Regions are based on designations in Lazardis et al 2014 (Africa, America, East Asia, Middle East, Qatar, South Asia, Central Asia / Siberia, Oceania, West Eurasia) and the 1000 Genomes website (AFR, AMR, EAS, EUR, EASN, SASN, WAFR), where 3-letter codes are used for Phase 1 and 4-letter codes are used for Phase 3.

	-		K (ADMIXTURE K=12)											
Study	n	1	2	3	4	5	6	7	8	9	10	11	12	
Inferred origin		Euro- pean	East Asian	Siberian	South Asian	Bedouin	African Pygmy	Oceanian	Arab	Persian	Sub-Saharan African	American	Central Asian	
Qatar Genome	108	0	0	0	4	48	0	0	20	19	17	0	0	
Qatar Exome	1053	5	0	0	78	518	1	0	216	175	60	0	0	
in Qatar Exome	215	11	2	0	49	35	2	0	9	94	13	0	0	
Human Origins	1862	418	195	103	176	65	51	27	0	353	184	100	190	
1000Gp1	1028	391	238	0	0	0	0	0	0	53	213	85	48	
1000Gp3	1345	134	212	0	457	0	0	0	0	23	408	103	8	
Public data	4235	943	645	103	633	65	51	27	0	429	805	288	246	
Qatar	1161	5	0	0	82	566	1	0	236	194	77	0	0	
Total	2373	525	450	0	457	0	0	0	0	76	621	188	56	

Supplemental Table III. Population structure analysis<sup>1</sup>

Summary of population structure analysis using ADMIXTURE. Genotypes were obtained for 2265 SNPs in a combined set of 5611 individuals, including 1161 Qataris (108 genomes and 1053 exomes), 215 s living in Qatar, 1862 from Human Origins dataset<sup>42</sup>, 1028 from 1000 Genomes Phase 1 not in Human Origins<sup>40</sup>, and 1345 from 1000 Genomes Phase 3 not in Human Origins nor 1000 Genomes Phase 1. The set of SNPs used for the analysis were segregating in all three datasets, and were pruned using PLINK2<sup>13</sup> to exclude SNPs with Hardy-Weinberg equilibrium p-value < 1x10-6 and SNPs with linkage disequilibrium > 0.25 in 1000 SNP intervals (step size 25 SNPs). ADMIXTURE analysis was conducted K=12, based on lowest cross-validation error in a prior study<sup>16,17</sup>. The resulting ancestry proportions in 12 ancestral populations for each individual was used to assign each individual to a cluster for color-coding principal components analysis, based on the dominant ancestry for each individual. Shown is the total sample and number of individuals assigned to each of 12 clusters (K) for Qatari Exomes, Qatari Genomes, s in Qatar, Human Origins, 1000 Genomes Phase 1, 1000 Genomes Phase 3, and totals for public data (Human Origins, 1000 Genomes Phase 1 and 1000 Genomes Phase 3) and Qatari data (Qatar Genome and Qatar Exome). Cluster names "inferred origin" is based on the major populations present in the cluster.

San	ıple			
1 <sup>st</sup>	$2^{\mathrm{nd}}$	Inferred relation	Kept	Pairs (n)
Qatari	Qatari	3	both	294
Qatari	Qatari	1	one	110
Qatari	Qatari	3	one	106
Non-Qatari	Non-Qatari	1	neither	87
Qatari	Qatari	2	one	55
Qatari	Qatari	1	neither	38
Non-Qatari	Non-Qatari	3	both	10
Qatari	Qatari	3	neither	9
Qatari	Qatari	2	neither	5
Non-Qatari	Non-Qatari	2	one	4
Non-Qatari	Non-Qatari	3	one	4
Qatari	Qatari	2	both	4
Qatari	Non-Qatari	1	neither	3
Non-Qatari	Non-Qatari	2	neither	2
Qatari	Non-Qatari	3	one	2
Qatari	Non-Qatari	1	one	1
Qatari	Non-Qatari	2	one	1
Qatari	Non-Qatari	3	both	1
Non-Qatari	Non-Qatari	1	both	0
Non-Qatari	Non-Qatari	2	both	0
Non-Qatari	Non-Qatari	3	neither	0
Qatari	Non-Qatari	1	both	0
Qatari	Non-Qatari	2	both	0
Qatari	Non-Qatari	2	neither	0
Qatari	Non-Qatari	3	neither	0
Qatari	Qatari	1	both	0

#### Supplemental Table IV. Relatives Identified in 1376 Qatari and Non-Qatari Exomes<sup>1</sup>

<sup>1</sup> SNPs were pruned from the initial 1376 individuals' exome datasets of 767,274 SNPs based on surrounding linkage disequilibrium (LD) structure using PLINK 1.90's --indep-pairwise option with window sizes of 1000 SNPs, overlaps of 25 SNPs, and SNPs with LD > 0.25 pruned out. This left 381,028 SNPs for analysis. Manichaikul et al.'s<sup>19</sup> program for estimating kinship coefficients between pairs of individuals, KING-robust v1.4, was then applied to this filtered dataset using the flag --kinship. None of the known pedigree information was included in the KING analysis. Degree of relatedness was inferred via cutoffs provided in the Manichaikul et al.<sup>19</sup> paper, except for our second degree lower bound value (0.1101) which was chosen based on an analysis of SNP data from 1000 Genomes and HapMap on individuals with known relationships. Columns 1 and 2 of the table denote whether individual 1 and two are currently living in Qatar or are Non-Qataris, respectively. Column 3 is the relationship inferred by the KING-robust analysis. Column 4 denotes whether both, one, or neither individual was included in the subsequent analyses. Column 5 provides the number of pairs for which the prior columns' information applies to.

									SNP	s													Indels		
		Integra	ated (n=10	005)			Gen	ome (n=8	8)			Exome	50 Mb (n	=853)			Exon	ne 38 Mb (	(n=64)			G	enome (n=	<b>88</b> )	
		Nov	vel	Major al	t allele	_	Nov	vel	Major al	t allele	_	No	ovel	Majo l	r alt al- ele	_	N	ovel	Majo l	r alt al- ele	_	Nov	vel	Major alt	t allele
Chr	SNPs	Ν	%	Ν	%	SNPs	Ν	%	Ν	%	SNPs	Ν	%	Ν	%	SNPs	Ν	%	Ν	%	Indels	Ν	%	Ν	%
All	20,937,965	2,975,232	14.21%	1,931,122	9.22%	20,838,516	2,956,681	14.19%	1,931,067	9.27%	167,723	18,175	10.84%	7,567	4.51%	84,133	5,973	7.10%	7,065	8.40%	5,452,613	3,182,624	58.37%	1,882,405	34.52%
1	1,592,163	222,736	13.99%	149,248	9.37%	1,581,236	220,786	13.96%	149,224	9.44%	18,537	1,886	10.17%	860	4.64%	9,392	615	6.55%	781	8.32%	423,410	248,009	58.57%	143,511	33.89%
2	1,709,761	240,085	14.04%	154,410	9.03%	1,703,529	238,883	14.02%	154,421	9.06%	10,370	1,155	11.14%	489	4.72%	5,296	383	7.23%	458	8.65%	439,507	255,079	58.04%	148,206	33.72%
3	1,409,619	187,933	13.33%	129,413	9.18%	1,404,001	186,838	13.31%	129,414	9.22%	9,227	1,035	11.22%	400	4.34%	4,695	358	7.63%	385	8.20%	357,315	206,465	57.78%	120,288	33.66%
4	1,445,319	195,681	13.54%	144,549	10.00%	1,441,704	195,004	13.53%	144,551	10.03%	6,261	621	9.92%	305	4.87%	3,286	246	7.49%	291	8.86%	370,841	217,409	58.63%	125,936	33.96%
5	1,282,399	178,124	13.89%	114,208	8.91%	1,278,212	177,320	13.87%	114,208	8.93%	7,061	784	11.10%	388	5.49%	3,546	256	7.22%	366	10.32%	320,147	182,821	57.11%	109,029	34.06%
6	1,254,721	169,944	13.54%	119,019	9.49%	1,249,428	168,993	13.53%	119,020	9.53%	9,406	1,143	12.15%	447	4.75%	5,019	535	10.66%	409	8.15%	332,004	195,950	59.02%	114,112	34.37%
7	1,181,277	163,189	13.81%	105,329	8.92%	1,176,840	162,335	13.79%	105,324	8.95%	7,368	846	11.48%	262	3.56%	3,689	271	7.35%	261	7.08%	310,413	181,560	58.49%	103,381	33.30%
8	1,121,946	154,901	13.81%	100,654	8.97%	1,118,463	154,271	13.79%	100,653	9.00%	5,741	620	10.80%	225	3.92%	2,778	185	6.66%	215	7.74%	263,130	153,087	58.18%	87,994	33.44%
9	893,371	124,547	13.94%	81,215	9.09%	889,068	123,746	13.92%	81,222	9.14%	7,154	778	10.88%	290	4.05%	3,493	237	6.78%	270	7.73%	220,843	126,445	57.26%	74,180	33.59%
10	1,011,674	132,809	13.13%	94,540	9.34%	1,007,822	132,100	13.11%	94,529	9.38%	6,692	663	9.91%	315	4.71%	3,453	229	6.63%	302	8.75%	262,781	152,899	58.18%	88,800	33.79%
11	992,815	133,836	13.48%	101,238	10.20%	986,571	132,732	13.45%	101,237	10.26%	10,547	1,100	10.43%	568	5.39%	5,359	328	6.12%	537	10.02%	246,040	142,728	58.01%	82,771	33.64%
12	950,274	127,170	13.38%	89,829	9.45%	945,483	126,273	13.36%	89,819	9.50%	8,066	871	10.80%	378	4.69%	4,078	280	6.87%	360	8.83%	258,803	149,851	57.90%	87,556	33.83%
13	721,704	94,831	13.14%	75,313	10.44%	720,085	94,533	13.13%	75,309	10.46%	2,783	291	10.46%	148	5.32%	1,457	110	7.55%	141	9.68%	192,835	115,031	59.65%	66,223	34.34%
14	657,214	90,851	13.82%	60,225	9.16%	654,196	90,281	13.80%	60,221	9.21%	5,139	585	11.38%	243	4.73%	2,603	163	6.26%	236	9.07%	169,405	97,754	57.70%	58,262	34.39%
15	605,125	86,523	14.30%	55,833	9.23%	602,017	85,933	14.27%	55,831	9.27%	5,182	571	11.02%	233	4.50%	2,624	180	6.86%	225	8.57%	157,232	91,850	58.42%	54,406	34.60%
16	667,442	97,950	14.68%	57,149	8.56%	662,638	97,058	14.65%	57,150	8.62%	7,894	882	11.17%	275	3.48%	3,630	270	7.44%	245	6.75%	161,821	94,228	58.23%	52,265	32.30%
17	573,728	83,775	14.60%	49,208	8.58%	567,883	82,664	14.56%	49,198	8.66%	9,903	1,074	10.85%	422	4.26%	4,821	330	6.85%	388	8.05%	165,430	96,122	58.10%	55,824	33.74%
18	567,901	74,034	13.04%	55,536	9.78%	566,489	73,776	13.02%	55,537	9.80%	2,472	248	10.03%	121	4.89%	1,290	85	6.59%	125	9.69%	146,951	85,698	58.32%	50,757	34.54%
19	478,025	66,775	13.97%	39,669	8.30%	470,516	65,330	13.88%	39,674	8.43%	12,734	1,441	11.32%	499	3.92%	5,900	366	6.20%	449	7.61%	141,734	81,136	57.25%	47,778	33.71%
20	456,002	58,746	12.88%	36,920	8.10%	453,008	58,231	12.85%	36,917	8.15%	5,099	475	9.32%	221	4.33%	2,482	151	6.08%	192	7.74%	120,911	72,303	59.80%	39,609	32.76%
21	297,875	42,861	14.39%	30,364	10.19%	296,542	42,658	14.39%	30,363	10.24%	2,316	193	8.33%	124	5.35%	1,141	58	5.08%	111	9.73%	87,587	54,374	62.08%	26,897	30.71%
22	289,339	39,574	13.68%	24,499	8.47%	286,767	39,142	13.65%	24,494	8.54%	4,404	432	9.81%	187	4.25%	2,082	118	5.67%	168	8.07%	76,727	46,370	60.44%	25,186	32.83%
Х	770,483	205,774	26.71%	61,856	8.03%	768,242	205,233	26.71%	61,854	8.05%	3,347	477	14.25%	166	4.96%	2,013	218	10.83%	149	7.40%	216,686	127,839	59.00%	115,824	53.45%
Y	7,110	2,239	31.49%	886	12.46%	7,098	2,235	31.49%	885	12.47%	20	4	20.00%	1	5.00%	6	1	16.67%	1	16.67%	10,036	7,594	75.67%	3,593	35.80%
MtDNA	678	344	50.74%	12	1.77%	678	326	48.08%	12	1.77%	-	-	-	-	-	-	-	-	-	-	24	22	91.67%	17	70.83%

Supplemental Table V. Aggregated variants observed in 1005 unrelated Qatari (88 genomes, 917 exomes) and incorporated into the Qatar Reference Genome<sup>1</sup>

<sup>1</sup> In order to build a reference genome tailored to the Qatari population, SNP and indel variants were identified in 1,005 unrelated Qataris and both novel and major alternate alleles (MAA) were quantified. A total of 1,161 Qatari DNA samples were sequenced, including 108 selected for genome sequencing and 1,053 selected for exome sequencing. The exome sequencing subjects included n=67 sequenced on the Illumina platform using DNA captured with targets in the Agilent SureSelect Human All Exon 38 Mb platform (Exome38Mb), as well as n=1201 sequenced on the Illumina platform using DNA captured with targets in the Agilent SureSelect Human All Exon 51 Mb platform (Exome51Mb). Variants were identified in each genome or exome using the GATK best practices workflow<sup>8</sup>, and the data was integrated using batch-specific filters that ensured a consistent <0.73% novel SNP build 146) across platforms in coding intervals covered by all three platforms. Related individuals were identified using variants in the intersection of the three platforms, exclusion of 1st degree and 2nd degree relatives resulted in n=1,005 Qatari, including n=88 genomes and n=917 exomes (n=64 Exome38Mb and n=853 Exome51Mb). The variants frequency was calculated across the n=1,005 Qataris individuals using a Python<sup>43</sup> script, and novel variants were identified using VCFtools<sup>22</sup>. Shown is the total number of SNPs in the integrated set, the number and percentage of novel SNPs, and the number and percentage of MAA SNPs. The same columns are repeated for genome SNPs, Exome 50Mb SNPs, Exome38Mb SNPs, and genome indels. The indels were identified using the CASAVA 1.9 workflow<sup>6</sup>.

#### Supplemental Table VI. Impact of Using QTRG3 on Depth and Variant Sites in Quadruple Sequenced Qatari<sup>1</sup>

	GRC	h37	QTR	G3		QTRG3 minus GRCh37
		Mean		Mean	Vari-	
Platform/batch	Variants	depth	Variants	depth	ants	Mean depth
Genome HiSeq 2500	369	31	331	32	-38	+1
Genome HiSeq X	369	30	331	32	-38	+2
Exome38Mb	369	83	331	79	-38	-4
Exome51Mb	369	90	331	74	-38	-6

In order to quantify differences in read depth and variant discovery between QTRG3 and GRCh37 references, sequence data from four platforms (2 genome, 2 exome) was analyzed using GATK Best Practices Workflow<sup>8</sup> twice, once using GRCh37 as the reference and once using QTRG3 as the reference. Shown are the results for Chr20 coding intervals covered in the intersection of the four platforms (Genome HiSeq 2500, Genome HiSeq X, Exome38Mb, Exome51Mb). Calls were filtered to sites covered at least 12\* in all four platforms. Shown is the total number of variants observed and mean depth at variant sites for QTRG3, and the difference in total variants and mean depth (negative means lower in QTRG3). Analysis was conducted using VCFtools<sup>22</sup> and Python<sup>43</sup> scripts.

	Dej	pth at varia	nt sit	es		Variants								
	Obse	erved	Inc	crease	Obse	erved	Redu	ction		Expected				
Individual	GRCh37	QTRG3	X	%	GRCh37	QTRG3	Ν	%	Ν	%	E-O			
Mean	31	38	7	23%	4,843,626	4,086,955	756,671	16%	1,963,417	41%	25%			
QMD-27-01	30	34	4	14%	4,713,827	3,898,685	815,142	17%	1,962,206	42%	24%			
QMD-27-02	26	32	6	21%	4,777,169	4,017,524	759,645	16%	1,956,241	41%	25%			
QMD-27-04	30	37	7	24%	4,827,926	4,051,563	776,363	16%	1,970,911	41%	25%			
QMD-27-05	27	32	5	19%	4,841,023	4,096,170	744,853	15%	1,953,194	40%	25%			
QMD-27-06	30	38	8	26%	4,862,510	4,100,252	762,258	16%	1,968,086	40%	25%			
QMD-27-07	28	35	7	25%	4,788,903	4,063,026	725,877	15%	1,943,632	41%	25%			
QMD-27-08	32	40	8	24%	4,891,588	4,137,736	753,852	15%	1,961,483	40%	25%			
QMD-27-09	30	37	7	22%	4,862,523	4,106,822	755,701	16%	1,970,489	41%	25%			
QMD-27-10	31	38	7	23%	4,814,774	4,062,059	752,715	16%	1,961,938	41%	25%			
QMD-27-11	43	52	9	22%	4,949,852	4,199,328	750,524	15%	1,974,219	40%	25%			
QMD-27-12	30	36	6	19%	4,833,472	4,078,511	754,961	16%	1,969,131	41%	25%			
QMD-27-13	31	38	7	24%	4,870,552	4,114,454	756,098	16%	1,962,077	40%	25%			
QMD-27-14	32	41	9	27%	4,888,960	4,144,546	744,414	15%	1,969,268	40%	25%			
QMD-27-15	31	39	8	25%	4,889,792	4,137,013	752,779	15%	1,967,142	40%	25%			
QMD-27-16	31	39	8	24%	4,841,519	4,096,639	744,880	15%	1,961,233	41%	25%			

Supplemental Table VII. Coverage Depth Increase and Variant Call Reduction Using QTRG3 on a Large Qatari Family<sup>1</sup>

<sup>1</sup> In order to study the impact of a modified reference on genome interpretation, n=15 Qatari genomes from a family of K=9 Persian ancestry were sequenced, and reads were mapped to both GRCh37 and QTRG3 and analyzed using GATK best practices<sup>8</sup>. Genome-wide mapped read depth at variant sites and number of variant sites per genome was quantified using VCFtools<sup>22</sup>, limited to sites covered with at least 12\* depth. Shown is the mean and individual depth for GRCH37, depth for QTRG3, and the increased depth using QTRG3 (X depth and percentage of GRCh37 depth); the total number of variants in GRCh37 and QTRG3, and the reduction using QTRG3 (number and % of GRCh37); the expected reduction (number of flipped variants) and percentage, and the difference between observed and expected reduction (E-O).

			Variants in Chr20										
						QTRO	53						
	Sample inform	nation	Gro	h37	Exp	ected	Observed						
		ADMIXTURE	Vari-			Reduction	Vari-	Reduction					
ID	Batch	Cluster	ants	MAA	Variants	(%)	ants	(%)					
DGMQ-31034	Exome51Mb	K=8 Arab	1,937	758	1,179	39%	556	71%					
DGMQ-31094	Exome51Mb	K=9 Persian	1,675	657	1,018	39%	470	72%					
DGMQ-31164	Exome51Mb	K=5 Bedouin	1,667	674	993	40%	470	72%					
DGMQ-31203	Exome51Mb	K=5 Bedouin	1,962	766	1,196	39%	548	72%					
DGMQ-31517	Exome51Mb	K=4 South Asian	1,737	641	1,096	37%	557	68%					
DGMQ-31721	Exome51Mb	K=5 Bedouin	2,250	878	1,372	39%	589	74%					
DGMQ-31728	Exome51Mb	K=9 Persian	1,587	564	1,023	36%	503	68%					
DGMQ-31790	Exome51Mb	K=9 Persian	2,204	842	1,362	38%	587	73%					
DGMQ-32543	Exome51Mb	K=8 Arab	1,734	733	1,001	42%	444	74%					
DGMQ-32513	Exome51Mb	K=10 Sub-Saharan African	2,397	733	1,664	31%	788	67%					
DGMQ-33173	Exome51Mb	K=10 Sub-Saharan African	2,164	682	1,482	32%	640	70%					
DGMQ-33708	Exome51Mb	K=10 Sub-Saharan African	2,092	636	1,456	30%	681	67%					
DGMQ-33147	Exome51Mb	K=8 Arab	1,598	622	976	39%	476	70%					
DGMQ-33553	Exome51Mb	K=5 Bedouin	1,866	750	1,116	40%	450	76%					
DGMQ-33557	Exome51Mb	K=5 Bedouin	1,847	749	1,098	41%	515	72%					
DGMQ-31923	Exome51Mb	K=8 Arab	1,851	723	1,128	39%	549	70%					

#### Supplemental Table VIII. Evaluation of QTRG3 on a Diverse Panel of Qatari Exomes<sup>1</sup>

<sup>1</sup> In order to quantify the impact of using the QTRG3 reference on variant discovery, n=16 exomes from diverse ancestries were mapped to both the GRCh37 and QTRG3 reference genomes, and variants were identified using GATK best practices<sup>8</sup>. Shown is the sample ID, the sequencing batch, the inferred ancestry cluster, the number of variants observed with respect to GRCh37 on Chr20 at, the number of variants that were modified in the reference that are present in this individual, the expected and observed number of variants and percent reduction of variants compared to GRCh37 mapping. The expected variants is equal to the GRCh37 variants minus the flipped in QTRG3 variants, while the observed variants is based on mapping to QTRG3. The reduction is significant with a Chi-square test p value < 0.001.

		All var	iants	Major alt all	eles (MAA)
Impact	Function	n	%	n	%
	All	26,390,578	100.00%	3,827,678	100.00%
High	Likely pathogenic	12,721	0.05%	1,622	0.04%
Moderate	Potentially pathogenic	164,821	0.62%	8,944	0.23%
Low	Unlikely pathogenic	4,357,128	16.51%	621,631	16.24%
Modifier	Likely benign	21,855,908	82.82%	3,195,481	83.48%
High	Frameshift variant	2,888	0.01%	617.0	0.02%
	Stop gained	2,361	0.01%	43.0	0.00%
	Splice donor variant & intron variant	2,193	0.01%	268.0	0.01%
	Splice acceptor variant & intron variant	1,799	0.01%	289.0	0.01%
	Protein protein contact	1,023	< 0.01%	18.0	< 0.01%
	Frameshift variant & stop gained	421	$<\!\!0.01\%$	26.0	< 0.01%
	Start lost	374	< 0.01%	21.0	< 0.01%
	Stop lost	293	< 0.01%	38.0	< 0.01%
	Frameshift variant & splice region variant	213	< 0.01%	72.0	< 0.01%
	Stop gained & inframe insertion	101	< 0.01%	8.0	< 0.01%
	Splice donor variant & splice region variant & intron variant & non coding exon variant	94	< 0.01%	14.0	< 0.01%
	Splice acceptor variant & splice region variant & intron variant	94	< 0.01%	37.0	< 0.01%
	Splice acceptor variant & splice region variant & intron variant & non coding exon variant	87	< 0.01%	18.0	< 0.01%
	Stop gained & splice region variant	80	< 0.01%	3.0	< 0.01%
	Stop gained & disruptive inframe insertion	70	< 0.01%	5.0	< 0.01%
	Frameshift variant & stop gained & splice region variant	68	< 0.01%	12.0	< 0.01%
	Splice donor variant & splice region variant & intron variant	61	< 0.01%	17.0	< 0.01%
	Splice acceptor variant & splice donor variant & intron variant	55	< 0.01%	35.0	< 0.01%
	Splice acceptor variant & splice donor variant & splice region variant & intron variant & non coding exon variant	49	< 0.01%	7.0	< 0.01%
	Frameshift variant & stop lost	38	< 0.01%	10.0	< 0.01%
	Frameshift variant & start lost	37	< 0.01%	12.0	< 0.01%
	Frameshift variant & splice acceptor variant & splice region variant & intron variant	28	< 0.01%	7.0	< 0.01%
	Splice donor variant & splice region variant & 5 prime UTR variant & intron variant	25	< 0.01%	2.0	< 0.01%
	Frameshift variant & splice donor variant & splice region variant & intron variant	24	< 0.01%	6.0	< 0.01%
	Exon loss variant & splice acceptor variant & splice donor variant & splice region variant & intron variant	23	< 0.01%	0.0	< 0.01%
	Stop lost & splice region variant	19	< 0.01%	4.0	< 0.01%
	Transcript ablation	18	< 0.01%	3.0	< 0.01%
	Stop gained & inframe insertion & splice region variant	15	< 0.01%	0.0	< 0.01%
	Splice acceptor variant & splice donor variant & splice region variant & intron variant	14	< 0.01%	3.0	< 0.01%
	Frameshift variant & stop lost & splice region variant	10	< 0.01%	0.0	< 0.01%
	Start lost & splice region variant	10	< 0.01%	1.0	< 0.01%
	Splice donor variant & disruptive inframe deletion & splice region variant & intron variant	9	< 0.01%	2.0	< 0.01%

# Supplemental Table IX. Functional Classification of Variants in Qatar<sup>1</sup>

# Supplemental Table IX. Functional Classification of Variants in Qatar<sup>1</sup> (cont., page 2)

		All var	iants	Major alt all	eles (MAA)	
Impact	Function	n	%	n	%	
	Splice donor variant & splice region variant & 3 prime UTR variant & intron variant	8	<0.01%	3.0	< 0.01%	
	Start lost & inframe deletion	8	< 0.01%	3.0	< 0.01%	
	Splice acceptor variant & splice region variant & 3 prime UTR variant & intron variant	8	<0.01%	5.0	< 0.01%	
	Stop lost & inframe deletion	7	< 0.01%	0.0	< 0.01%	
	Splice acceptor variant & inframe deletion & splice region variant & intron variant	6	< 0.01%	2.0	< 0.01%	
	Splice donor variant & 5 prime UTR variant & intron variant	6	< 0.01%	2.0	< 0.01%	
	Splice acceptor variant & 5 prime UTR variant & intron variant	5	< 0.01%	0.0	< 0.01%	
	Frameshift variant & splice acceptor variant & splice donor variant & splice region variant & intron variant	5	< 0.01%	0.0	< 0.01%	
	Frameshift variant & start lost & splice region variant	5	<0.01%	2.0	< 0.01%	
	Splice acceptor variant & splice region variant & 5 prime UTR variant & intron variant	5	< 0.01%	0.0	< 0.01%	
	Stop gained & disruptive inframe insertion & splice region variant	5	< 0.01%	0.0	< 0.01%	
	Start lost & disruptive inframe insertion	4	< 0.01%	1.0	< 0.01%	
	Splice acceptor variant & splice donor variant & 5 prime UTR truncation & exon loss variant & splice region variant & intron variant	4	< 0.01%	0.0	< 0.01%	
	Splice donor variant & 5 prime UTR truncation & exon loss variant & splice region variant & intron variant	4	< 0.01%	0.0	< 0.01%	
	Frameshift variant & missense variant	3	< 0.01%	0.0	< 0.01%	
	Splice acceptor variant & splice donor variant & splice region variant & 3 prime UTR variant & intron variant	3	< 0.01%	0.0	< 0.01%	
	Splice donor variant & 3 prime UTR variant & intron variant	3	< 0.01%	0.0	< 0.01%	
	Exon loss variant & splice acceptor variant & splice donor variant & 3 prime UTR truncation & exon loss variant & splice region variant & intron variant	3	< 0.01%	1.0	< 0.01%	
	Splice acceptor variant & disruptive inframe deletion & splice region variant & intron variant	3	< 0.01%	1.0	< 0.01%	
	Splice acceptor variant & splice donor variant & disruptive inframe deletion & splice region variant & intron variant	3	< 0.01%	0.0	< 0.01%	
	Splice donor variant & inframe deletion & splice region variant & intron variant	3	< 0.01%	0.0	< 0.01%	
	Start lost & inframe insertion	3	< 0.01%	1.0	< 0.01%	
	Stop gained & disruptive inframe deletion	3	< 0.01%	0.0	< 0.01%	
	Frameshift variant & missense variant & splice region variant	2	< 0.01%	0.0	< 0.01%	
	Exon loss variant & splice acceptor variant & splice region variant & intron variant	2	< 0.01%	0.0	< 0.01%	
	Exon loss variant & splice donor variant & splice region variant & intron variant	2	< 0.01%	2.0	< 0.01%	
	Exon loss variant & splice region variant	2	< 0.01%	0.0	< 0.01%	
	Start lost & disruptive inframe deletion	2	< 0.01%	0.0	< 0.01%	
	Stop lost & inframe deletion & splice region variant	2	< 0.01%	0.0	< 0.01%	
	Exon loss variant	1	< 0.01%	0.0	< 0.01%	
	Frameshift variant & splice acceptor variant & missense variant & splice region variant & intron variant	1	< 0.01%	0.0	< 0.01%	
	Frameshift variant & splice donor variant & splice region variant & synonymous variant & intron variant	1	< 0.01%	0.0	< 0.01%	
	Frameshift variant & stop gained & stop retained variant	1	< 0.01%	0.0	< 0.01%	
	Splice acceptor variant & missense variant & inframe insertion & splice region variant & intron variant	1	< 0.01%	0.0	< 0.01%	
	Splice acceptor variant & splice donor variant & inframe deletion & splice region variant & intron variant	1	< 0.01%	0.0	< 0.01%	
	Splice acceptor variant & splice donor variant & splice region variant & 5 prime UTR variant & intron variant	1	< 0.01%	0.0	< 0.01%	
	Stop gained & splice acceptor variant & missense variant & inframe insertion & splice region variant & intron variant	1	< 0.01%	1.0	< 0.01%	
Moderate	Missense variant	144,405	0.55%	6,039.0	0.16%	
	Sequence feature	13,953	0.05%	1,950.0	0.05%	
	Missense variant & splice region variant	3,179	0.01%	138.0	0.00%	

		All vari	ants	<u>Major alt alleles (MAA)</u>	
Impact	Function	n	%	n	%
	Disruptive inframe deletion	1,208	< 0.01%	292.0	0.01%
	Disruptive inframe insertion	764	< 0.01%	214.0	0.01%
	Inframe insertion	662	< 0.01%	173.0	< 0.01%
	Inframe deletion	562	< 0.01%	124.0	< 0.01%
	Inframe insertion & splice region variant	48	< 0.01%	9.0	< 0.01%
	Disruptive inframe deletion & splice region variant	13	< 0.01%	1.0	< 0.01%
	Inframe deletion & splice region variant	12	< 0.01%	3.0	< 0.01%
	Disruptive inframe insertion & splice region variant	11	< 0.01%	0.0	< 0.01%
	Missense variant & disruptive inframe insertion	1	< 0.01%	0.0	< 0.01%
	5 prime UTR truncation & exon loss variant	1	< 0.01%	0.0	< 0.01%
	Missense variant & inframe insertion	1	< 0.01%	1.0	< 0.01%
	Missense variant & inframe insertion & splice region variant	1	< 0.01%	0.0	< 0.01%
Low	Sequence feature	4,191,317	15.88%	607,205.0	15.86%
	Synonymous variant	108,870	0.41%	6,041.0	0.16%
	Splice region variant & intron variant	24,115	0.09%	4,477.0	0.12%
	5 prime UTR premature start codon gain variant	10,353	0.04%	726.0	0.02%
	TF binding site variant	10,053	0.04%	1,388.0	0.04%
	Splice region variant & non coding exon variant	6,253	0.02%	1,103.0	0.03%
	Splice region variant	2,830	0.01%	469.0	0.01%
	Splice region variant & synonymous variant	2,551	0.01%	130.0	< 0.01%
	TFBS ablation	636	< 0.01%	83.0	< 0.01%
	Stop retained variant	109	< 0.01%	6.0	< 0.01%
	Initiator codon variant	27	< 0.01%	2.0	< 0.01%
	Splice region variant & stop retained variant	13	< 0.01%	0.0	< 0.01%
	Splice region variant & downstream gene variant	1	< 0.01%	1.0	< 0.01%
Modifier	Intergenic region	10,100,190	38.27%	1,493,966.0	39.03%
	Intron variant	6,339,378	24.02%	914,967.0	23.90%
	Upstream gene variant	2,912,384	11.04%	425,612.0	11.12%
	Downstream gene variant	2,132,880	8.08%	311,645.0	8.14%
	3 prime UTR variant	230,874	0.87%	32,038.0	0.84%
	Non coding exon variant	74,461	0.28%	9,087.0	0.24%
	5 prime UTR variant	58,106	0.22%	7,413.0	0.19%
	TF binding site variant	5,501	0.02%	424.0	0.01%
	Intragenic variant	2,134	0.01%	329.0	0.01%

### Supplemental Table IX. Functional Classification of Variants in Qatar<sup>1</sup> (cont., page 3)

Variants (SNPs and indels) were functionally annotated using SnpEff<sup>29</sup> using ENSEMBL build 75<sup>28</sup> gene models. Shown are the counts of variants, grouped by functional category. The number of variants is shown for all SNPs and for major allele SNPs, and the percentages of the total number of SNPs (top row). Top section lists all SNPs, middle section list subsets of potentially pathogenic and unlikely pathogenic, and third section lists details of each annotated variant category. Categories are organized from top to bottom by decreasing pathogenicity and decreasing n.

	Inheritance	Reference		Gene	_	Position			cDNA		#0.	#0.	Oat.	FyAC.
<b>Disease</b> (s)	model	PMID	Gene	MIM	Chr	GRCh37	QTRG3	rsID	Change	A.A. Change	Hom	Het	MAF	MAF
Cowden-like Syndrome	Dominant (LO)	18678321	SDHB	185470	1	17354297	17354627	rs33927012	c.487T>C	p.Ser163Pro	0	12	0.60%	1.300%
Dominant deafness Type 2B	Dominant	9843210	GJB3	603324	1	35250910	35223785	rs74315318	c.547G>A	p.Glu183Lys	0	2	0.12%	0.051%
Mcad Deficiency	Dominant (SD)	9158144	ACADM	607008	1	76199288	76198878	rs12143428	3 c.461C>T	p.Thr154Ile	0	7	0.41%	0.001%
Diamond-blackfan anemia	Dominant (RP)	19061985	RPL5	603634	1	93301840	35817017	rs12143440	5 c.418G>A	p.Gly140Ser	0	3	1.71%	0.013%
Fundus Flavimaculatus	Dominant (SD)	9781034	ABCA4	601691	1	94473287	94472343	rs28938473	c.5908C>T	p.Leu1970Phe	0	2	0.12%	0.290%
Stargardt Disease 1	Dominant (SD)	9973280	ABCA4	601691	1	94473807	94472863	rs1800553	c.5882G>A	p.Gly1961Glu	0	36	1.79%	0.505%
Stargardt Disease 1	Dominant (SD)	9054934	ABCA4	601691	1	94512602	94511636	rs58331765	c.2791G>A	p.Val931Met	0	2	0.11%	0.049%
Erythrocyte Lactate Transporter Deficiency	Dominant (M)	10590411	SLC16A1	600682	1	113456602	113455493	rs72552271	c.1414G>A	p.Gly472Arg	0	4	0.23%	0.015%
Thrombophilia due to Factor 5 Leiden	Dominant (RP)	3110773	F5	612309	1	169519049	169517298	rs6025	c.1601A>G	p.Gln534Arg	0	14	0.70%	97.800%
Hereditary Prostate Cancer	Dominant (LO)	11799394	RNASEL	180435	1	182555149	182553554	rs74315364	c.793G>T	p.Glu265*	0	5	0.29%	0.399%
Familial autoinflammatory Syndrome	Dominant	49161	NLRP3	606416	1	247587343	247585369	rs12190814	7 c.598G>A	p.Val200Met	0	10	0.55%	0.823%
Primary Glaucoma	Dominant (LO)	15342693	CYP1B1	601771	2	38302291	38302637	rs9282671	c.241T>A	p.Tyr81Asn	0	3	0.19%	0.345%
Atrioventricularseptal Defect	Dominant (RP)	12632326	CRELD1	607170	3	9985136	9984961	rs28942091	c.985C>T	p.Arg329Cys	0	2	0.12%	0.063%
Heterotaxy Syndrome	Dominant	9916847	ACVR2B	602730	3	38518844	38518610	rs12143443	7 c.119G>A	p.Arg40His	0	5	0.27%	0.137%
Telomere-related Bone Marrow Failure	Dominant (RP)	15814878	TERT	187270	5	1294397	1294427	rs12191866	l c.604G>A	p.Ala202Thr	0	2	0.12%	0.023%
Familial adenomatous polyposis 1	Dominant (LO)	11001924	APC	611731	5	112175240	112175677	rs1801166	c.3949G>C	p.Glu1317Gln	0	32	1.59%	0.413%
Tetralogy of Fallot	Dominant (RP)	16418214	NKX2-5	600584	5	172662014	172662883	rs28936670	c.73C>T	p.Arg25Cys	0	11	0.56%	0.371%
Tetralogy of Fallot	Dominant (RP)	11714651	NKX2-5	600584	5	172662026	172662895	rs104893904	4 c.61G>C	p.Glu21Gln	0	4	0.24%	0.078%
Thiopurine S-methyltransferase Deficiency	Dominant (SD)	9931346	TPMT	187680	6	18130993	18131172	rs56161402	c.644G>A	p.Arg215His	0	4	0.26%	0.204%
Hemochromatosis	Dominant	10194428	HFE	613609	6	26091185	26091026	rs1800730	c.193A>T	p.Ser65Cys	0	2	0.12%	1.000%
Galbladder Disease 1	Dominant (LO)	3459187	ABCB4	171060	7	87082273	20682533	rs58238559	c.523A>G	p.Thr175Ala	1	9	0.64%	1.100%
Prostate Cancer	Dominant	12244320	MSR1	153622	8	16012594	16012318	rs41341748	c.931C>T	p.Arg311*	0	6	0.35%	0.735%
Prostate Cancer	Dominant	12244320	MSR1	153622	8	16026077	16025799	rs72552387	c.574G>T	p.Asp192Tyr	0	10	0.50%	0.197%
Familial Hyperlipidemia	Dominant (RP)	8541837	LPL	609708	8	19813529	19812860	rs268	c.953A>G	p.Asn318Ser	0	4	0.23%	1.300%
Multiple Endocrine Neoplasia	Dominant (RP)	12466368	RET	164761	10	43609990	43609141	rs77711105	c.1942G>A	p.Val648Ile	0	5	0.27%	0.009%
Recessive Visceral Heterotaxy 5	Dominant (RP)	9354794	NODAL	601265	10	72195385	72194808	rs10489416	9 c.548G>A	p.Arg183Gln	0	2	0.12%	0.012%
Dilated Cardiomyopathy	Dominant (LO)	14662268	LDB3	605906	10	88446830	88445588	rs12190833	8 c.694G>A	p.Asp232Asn	0	4	2.27%	0.454%
Cowden-like Syndrome	Dominant (LO)	18678321	SDHD	602690	11	111958677	111957252	rs11214077	c.149A>G	p.His50Arg	0	3	0.16%	0.652%
Acute Porphyria	Dominant (M)	8262523	HMBS	609806	11	118963216	118961755	rs11820411	3 c.754G>A	p.Ala252Thr	0	8	0.43%	-
Cirrhosis	Dominant (LO)	11372009	KRT8	148060	12	53298582	53298312	rs11554495	c.268G>T	p.Gly90Cys	0	3	0.36%	0.505%
Cirrhosis	Dominant (LO)	11372009	KRT8	148060	12	53298606	53298336	rs57749775	c.244T>C	p.Tyr82His	0	2	0.20%	0.199%
Dominant deafness Type 3B	Dominant	10471490	GJB6	604418	13	20797606	20717395	rs104894414	4 c.14C>T	p.Thr5Met	0	2	0.12%	0.003%
Hereditary Nonpolyposis Colon Cancer Type										-				
7	Dominant (RP)	12702580	MLH3	604395	14	75514138	75514289	rs28756990	c.2221G>T	p.Val741Phe	0	31	1.54%	1.500%

Supplemental Table X. Known Pathogenic Mendelian Mutations Observed in Two or More Qataris<sup>1</sup>

	Inheritance	Reference		Gene		Posit	ion	— cDNA				#O-	Oat-	ExAC-
<b>Disease</b> (s)	model	PMID	Gene	MIM	Chr	GRCh37	OTRG3	rsID	Change	A.A. Change	Hom	Het	MAF	MAF
Childhood absence epilepsy 5	Dominant (RP)	18514161	GABRB3	137192	15	27018841	27019151	rs25409	c.31C>T	p.Pro11Ser	0	9	0.56%	0.235%
Spherocytosis Type 4 Anemia, Band 3 Tuca-	× ,									1				
loosa	Dominant	1378323	SLC4A1	109270	17	42335888	42335820	rs28931583	c.980C>G	p.Pro327Arg	0	4	0.21%	0.024%
Hypophosphatemic osteoporosis	Dominant (LO)	18784102	SLC9A3R1	604990	17	72745313	72744916	rs35910969	c.328C>G	p.Leu110Val	0	8	0.58%	0.869%
Hypogonadotropic hypogonadism	Dominant	18272894	KISS1R	604161	19	920708	920748	rs121908499	e.1157G>C	p.Arg386Pro	0	2	0.11%	0.011%
Noninsullin-dependent Diabetes Mellitus	Dominant (RP)	8432414	INSR	147670	19	7125518	7125639	rs1799816	c.3034G>A	p.Val1012Met	Õ	37	1.84%	0.898%
Cystinuria	Dominant	11157794	SLC7A9	604144	19	33334838	33334502	rs121908484	4 c.997C>T	p.Arg333Trp	0	2	0.13%	0.009%
Cystinuria	Dominant	11157794	SLC7A9	604144	19	33353427	33353087	rs79389353	c.544G>A	p.Ala182Thr	0	3	0.19%	0.274%
Primary Open Angle Glaucoma	Dominant (RP)	19765683	NTF4	162662	19	49564992	49528991	rs61732310	c.263C>T	p.Ala88Val	0	17	0.90%	0.469%
Dominant Deafness	Dominant (M)	15015131	MYH14	608568	19	50747534	50747363	rs119103280	) c.1150G>T	p.Gly384Cys	0	3	1.71%	0.285%
Familial Hypertrophic Cardiomyopathy	Dominant (LO)	15070570	TNNI3	191044	19	55667607	55667367	rs77615401	c.244C>T	p.Pro82Ser	0	5	0.25%	0.164%
Keratoconus	Dominant (LO)	15623752	VSX1	605020	20	25062683	25062503	rs74315436	c.50T>C	p.Leu17Pro	0	2	0.17%	0.008%
Hypertrophic Cardiomyopathy	Dominant (M)	11733062	MYLK2	606566	20	30408160	30408106	rs121908108	3 c.284C>A	p.Ala95Glu	0	8	0.43%	0.078%
Long QT Syndrome	Dominant (M)	10219239	KCNE2	603796	21	35742947	35743144	rs74315448	c.170T>C	p.Ile57Thr	1	32	1.81%	0.088%
Becker Muscular Dystrophy	Dominant (M)	7881286	DMD	300377	Х	31496398	31495994	rs1800279	c.8762A>G	p.His2921Arg	1	38	3.43%	2.700%
Duchenne Muscular Dystrophy	Dominant	7881286	DMD	300377	Х	31496431	31496027	rs41305353	c.8729A>T	p.Glu2910Val	0	15	1.29%	2.100%
Non-fatal, non-progressive encephalopathy	Dominant (M)	11238684	MECP2	300005	Х	153295997	153295135	rs61753971	c.1318G>A	p.Gly440Ser	0	3	0.28%	0.012%
Recessive early-onset Parkinson Disease	Recessive	12953260	PARK7	602533	1	8044990	8045123	rs74315352	c.446A>C	p.Asp149Ala	0	3	0.16%	0.020%
Masp2 Deficiency	Recessive	12904520	MASP2	605102	1	11106666	11106808	rs72550870	c.359A>G	p.Asp120Gly	0	3	0.16%	2.200%
Limb-girdle muscular dystrophy	Recessive	18195152	POMGNT1	606822	1	46655645	46656025	rs74374973	c.1666G>A	p.Asp556Asn	0	6	0.33%	0.893%
Cystathioniuria	Recessive	12574942	CTH	607657	1	70881670	70777863	rs28941785	c.200C>T	p.Thr67Ile	0	3	0.16%	0.647%
Myopathy due to Myoadenylate Deaminase														
Deficiency	Recessive	10996775	AMPD1	102770	1	115220593	110169903	rs35859650	c.1261C>T	p.Arg421Trp	0	4	0.21%	0.068%
Gaucher Disease type I	Recessive	22713811	GBA	606463	1	155205043	155183055	rs421016	c.1448T>C	p.Leu483Pro	0	3	0.18%	0.316%
Recessive spherocytosis Type 3	Recessive	3785322	SPTA1	182860	1	158624528	158623150	rs35948326	c.2909C>A	p.Ala970Asp	0	11	0.64%	3.300%
Porphyria	Recessive	11286631	PPOX	600923	1	161138933	161137548	rs12735723	c.767C>G	p.Pro256Arg	0	2	0.12%	0.665%
Nephrotic Syndrome	Recessive	12464671	NPHS2	604766	1	179526214	179524646	rs61747728	c.686G>A	p.Arg229Gln	0	18	0.98%	2.900%
Nephrotic Syndrome	Recessive	10742096	NPHS2	604766	1	179544941	179543383	rs74315344	c.59C>T	p.Pro20Leu	0	6	0.40%	0.195%
Primary Glaucoma	Recessive (RP)	10655546	CYP1B1	601771	2	38298394	38298741	rs79204362	c.1103G>A	p.Arg368His	0	48	2.39%	0.596%
Rod Monochromacy (colorblindness)	Recessive	9662398	CNGA3	600053	2	99012480	99012626	rs104893613	3 c.859C>T	p.Arg287Trp	0	3	0.18%	0.014%
Recessive Thrombophilia due to Protein C														
Deficiency	Recessive	1678832	PROC	612283	2	128186038	128185850	rs121918144	4 c.1067C>T	p.Ala356Val	0	7	0.41%	-
Odontoonychodermal Dysplasia (Tooth agen-														
esis)	Recessive	19559398	WNT10A	606268	2	219755011	219752068	rs121908120	) c.682T>A	p.Phe228Ile	0	9	0.50%	1.300%
Long QT Syndrome	Recessive	17060380	CAV3	601253	3	8787330	8787143	rs72546668	c.233C>T	p.Thr78Met	0	20	1.01%	0.303%
Biotinidase Defieicency	Recessive	10400129	BTD	609019	3	15686693	15686407	rs13078881	c.1336G>C	p.Asp446His	0	35	1.74%	3.200%
Hurler Syndrome	Recessive	8328452	IDUA	252800	4	996555	996554	rs11934801	c.1291G>C	p.Gly431Arg	0	3	1.71%	0.388%

	Inheritance	Reference		Gene	Position		cDNA			#O-	# O ·	Oat-	ExAC-	
<b>Disease</b> (s)	model	PMID	Gene	MIM	Chr	GRCh37	OTRG3	rsID	Change	A.A. Change	Hom	Het	MAF	MAF
Hypogonadotropic hypogonadism	Recessive	9371856	GNRHR	138850	4	68619737	68618073	rs104893836	c.317A>G	p.Gln106Arg	0	2	0.12%	0.252%
Recessive Dyskeratosis Congenita	Recessive	15814878	TERT	187270	5	1293767	1293797	rs34094720	c.1234C>T	p.His412Tyr	1	3	0.29%	0.224%
Recessive Neuropathy	Recessive	16399879	CCT5	610150	5	10256175	10256372	rs118203986	c.440A>G	p.His147Arg	1	8	0.53%	0.004%
Central hypoventilation Syndrome	Recessive	9497256	GDNF	600837	5	37816112	37816039	rs36119840	c.328C>T	p.Arg110Trp	0	2	0.11%	0.221%
C7 Deficiency	Recessive	9218625	C7	217070	5	40955530	40955516	rs121964921	c.1135G>C	p.Gly379Arg	0	2	1.14%	0.013%
Laron Dwarfism	Recessive (M)	9814495	GHR	600946	5	42699970	42699907	rs6413484	c.484G>A	p.Val162Ile	0	3	0.18%	0.137%
Laron Dwarfism	Recessive (M)	7565946	GHR	600946	5	42700021	42699958	rs121909362	c.535C>T	p.Arg179Cys	0	2	0.12%	0.409%
Progressive Arthropathy	Recessive	10471507	WISP3	603400	6	112382323	112381757	rs17073260	c.232C>T	p.Arg78Cys	1	11	0.65%	0.937%
Recessive Parkinson disease 2 (juvenile)	Recessive	11487568	PARK2	602544	6	162683724	162683679	rs55774500	c.245C>A	p.Ala82Glu	0	4	0.21%	0.474%
Maple syrup Urine Disease	Recessive	9934985	DLD	238331	7	107555951	107555906	rs121964990	c.685G>T	p.Gly229Cys	0	4	0.23%	0.026%
Congenital Bilateral Absense of the Vas Def-														
erens	Recessive	1545465	CFTR	602421	7	117230454	117230209	rs1800098	c.1727G>C	p.Gly576Ala	0	4	0.24%	0.513%
Cystic Fibrosis	Recessive	7504969	CFTR	602421	7	117267807	117267564	rs75389940	c.3700A>G	p.Ile1234Val	0	9	0.53%	0.001%
Recessive myotonia	Recessive	11113225	CLCN1	118425	7	143048886	143048936	rs80356706	c.2795C>T	p.Pro932Leu	0	2	0.12%	0.014%
Retinitis pigmentosa	Recessive	15863674	RP1	603937	8	55537560	55536834	rs77775126	c.1118C>T	p.Thr373Ile	2	34	1.89%	1.300%
Recessive myopathy	Recessive	11528398	GNE	603824	9	36217396	36217255	rs28937594	c.2228T>C	p.Met743Thr	0	2	0.12%	0.003%
Aldolase B Deficiency	Recessive	3383242	ALDOB	612724	9	104189856	104188749	rs1800546	c.448G>C	p.Ala150Pro	0	3	0.18%	0.270%
Cockayne Syndrome Type B	Recessive	9443879	ERCC6	609413	10	50678722	50678022	rs4253208	c.3284C>G	p.Pro1095Arg	0	4	0.23%	0.378%
Hemophagocytic Lymphohistiocytosis (in-														
cluding non-hodgkin lymphoma)	Recessive (RP)	12229880	PRF1	170280	10	72360387	72359805	rs35947132	c.272C>T	p.Ala91Val	0	9	0.50%	3.100%
Dubin-Johnson Syndrome	Recessive	11477083	ABCC2	601107	10	101595950	101594812	rs72558201	c.3517A>T	p.Ile1173Phe	0	2	0.12%	0.002%
-	Recessive (M;									-				
Beta-Thalassemia	Mod)	16114182	HBB	141900	11	5248173	5248158	rs33950507	c.79G>A	p.Glu27Lys	0	4	0.21%	0.029%
Sickle Cell Anemia	Recessive	13852872	HBB	141900	11	5248232	5248217	rs334	c.20A>T	p.Glu7Val	0	3	1.71%	0.439%
	Recessive (M;									•				
Beta-Thalassemia	Mod)	2467892	HBD	142000	11	5255582	5248155	rs35152987	c.82G>T	p.Ala28Ser	0	7	0.41%	0.223%
Congenital Central Hypoventilation Syn-														
drome	Recessive	11840487	BDNF	113505	11	27680107	27678988	rs8192466	c.251C>T	p.Thr84Ile	0	24	1.19%	0.109%
Omenn Syndrome	Recessive	9630231	RAG1	179615	11	36596041	36594713	rs104894291	c.1187G>A	p.Arg396His	0	2	0.12%	0.002%
Oculocutaneous Albinism Type IA	Recessive	1642278	TYR	606933	11	88911770	88910230	rs63159160	c.649C>T	p.Arg217Trp	0	5	0.25%	0.020%
Oculocutaneous Albinism Type IB	Recessive	5516239	TYR	606933	11	89017973	49435662	rs104894313	c.1217C>T	p.Pro406Leu	1	3	0.27%	0.249%
Hyperalphalipoproteinemia 2	Recessive	24941082	APOC3	107720	11	116701353	116699867	rs76353203	c.109C>T	p.Arg37*	0	2	1.14%	0.068%
Recessive Bartter Syndrome	Recessive	8841184	KCNJ1	600359	11	128709126	17408421	rs59172778	c.1070T>C	p.Met357Thr	0	6	0.32%	0.802%
Adrenoleukodystrophy	Recessive	7719337	PEX5	600414	12	7362296	7362469	rs61752138	c.1641T>G	p.Asn547Lys	0	2	0.12%	-
Recessive Nephrogenic Diabetes Insipidus	Recessive	9048343	AQP2	107777	12	50344816	50344595	rs104894331	c.203A>C	p.Asn68Thr	0	24	1.33%	4.700%
Vitamin D Hydroxylation-Defiiency Rickets	Recessive	12050193	CYP27B1	609506	12	58159103	58158702	rs118204012	c.566A>G	p.Glu189Gly	0	8	0.45%	0.121%
Hyper-IgD Syndrome	Recessive	10369261	MVK	251170	12	110034320	110034227	rs28934897	c.1129G>A	p.Val377Ile	0	6	0.32%	0.140%

	Inheritance	Reference		Gene Position				cDNA				# <b>O</b>	- Oat-	EvAC.
<b>Disease</b> (s)	model	PMID	Gene	MIM	Chr	GRCh37	OTRG3	rsID	Change	A.A. Change	Hom	" V Het	t MAF	MAF
Peeling skin Syndrome	Recessive	16380904	TGM5	603805	15	43552349	43552928	3 rs112292549	e.337G>T	p.Gly113Cys	0	3	0.18%	0.259%
Tay-sachs Disease	Recessive	2140574	HEXA	606869	15	72637817	72638091	l rs121907956	5 c.1529G>A	p.Arg510His	0	2	0.12%	0.007%
Fumarylacetoacetase Deficiency	Recessive	7977370	FAH	613871	15	80472526	80472708	3 rs11555096	c.1021C>T	p.Arg341Trp	1	9	0.55%	1.700%
Familial Mediterranean Fever	Recessive	9668175	MEFV	608107	16	3293403	3293353	3 rs104895094	4 c.2084A>G	p.Lys695Arg	0	3	0.18%	0.550%
	Recessive (Di-													
Bardet-Biedl Syndrome 2	genic)	11567139	BBS2	606151	16	56548501	56548300	) rs4784677	c.209G>A	p.Asn70Ser	1	10	0.60%	0.600%
Congenital Myasthenic syndrome	Recessive	8755487	CHRNE	100725	17	4805239	4805392	2 rs121909516	5 c.488C>G	p.Ser163Trp	0	4	0.24%	0.003%
Congenital ichthyosiform Erythrodermia	Recessive	16116617	ALOXE3	607206	17	8015486	7946150	) rs121434235	5 c.1177T>A	p.Leu393Met	0	12	0.70%	0.558%
Smith-Magenic Syndrome	Recessive	11735029	MYO15A	602666	17	18051447	18051368	8 rs121908970	) c.6614C>T	p.Thr2205Ile	0	2	0.12%	0.417%
Myeloperoxidase Deficiency	Recessive	9354683	MPO	606989	17	56356502	56272604	trs56378716	c.848T>C	p.Met283Thr	0	12	0.64%	1.000%
Erythropoietic protoporphyria	Recessive	1755842	FECH	612386	18	55226380	55226136	5 rs118204037	7 c.819G>A	p.Met273Ile	0	17	0.85%	0.109%
Hypogonadotropic hypogonadism	Recessive	17164310	KISS1R	604161	19	918604	918644	4 rs104894703	3 c.305T>C	p.Leu102Pro	0	5	0.30%	0.003%
Dominant hyperlipoprotenemia Type 3	Recessive	9649566	APOE	107741	19	45412040	45411899	9 rs769455	c.487C>T	p.Arg163Cys	0	4	0.35%	0.123%
Limb-girdle muscular dystrophy	Recessive	14647208	FKRP	606596	19	47258942	47258803	3 rs104894683	3 c.235G>A	p.Val79Met	0	6	0.35%	0.117%
Kallmann Syndrome	Recessive	17054399	PROKR2	607123	20	5294762	5294846	5 rs74315418	c.254G>A	p.Arg85His	0	3	0.18%	0.074%
Adenomise Deaminase Deficiency	Recessive	2166947	ADA	608958	20	43255233	43255235	5 rs121908736	5 c.226C>T	p.Arg76Trp	0	2	0.11%	0.035%
Arterial Tortuosity Syndrome	Recessive	18565096	SLC2A10	606145	20	45353918	45353942	2 rs80358230	c.243C>G	p.Ser81Arg	2	15	0.95%	-
Homocystinuria	Recessive	10364517	CBS	613381	21	44483184	44483437	7 rs5742905	c.833T>C	p.Ile278Thr	0	98	4.89%	0.007%
Leukocyte adhesion Deficiency	Recessive	1346613	ITGB2	600065	21	46309312	46309674	4 rs5030672	c.1756C>T	p.Arg586Trp	0	3	0.18%	0.755%
Hyperprolinemia Type I	Recessive	17412540	PRODH	606810	22	18905859	18905888	3 rs2870984	c.1397C>T	p.Thr466Met	0	15	0.99%	0.573%
Schizophrenia and mild hyperprolinemia	Recessive	12217952	PRODH	606810	22	18905899	18905928	3 rs3970559	c.1357C>T	p.Arg453Cys	0	19	1.37%	1.200%
Schizophrenia and mild hyperprolinemia	Recessive	12217952	PRODH	606810	22	18905934	18905963	3 rs2904551	c.1322T>C	p.Leu441Pro	0	6	0.51%	0.575%
Glucose-6-Phosphate Dehydrogenase Defi-														
ciency	Recessive (M)	3393536	G6PD	305900	Х	153761205	153760352	2 rs5030869	c.1141G>A	p.Ala381Thr	0	2	0.20%	0.023%
Glucose-6-Phosphate Dehydrogenase Defi-	Recessive (M;													
ciency	Mod)	3393536	G6PD	305900	Х	153762634	153761781	rs5030868	c.563C>T	p.Ser188Phe	1	47	4.20%	0.310%
Glucose-6-Phosphate Dehydrogenase Defi-	Pagassiva	3303536	CAPD	305000	$\mathbf{v}$	153764371	152762510	ro76615161	a 143T>C	n Ila/18Thr	0	4	0 37%	0.001%
CICILLY	RECESSIVE	5575550	UUFD	202200	Λ	133/043/1	133/03310	515/0043401	U.1431/U	p.me401111	U	4	0.37%	0.001%

Curated list of known pathogenic Mendelian Disease causing mutations observed in at least 2 Qataris. Table is divided by inheritance patterns (dominant, recessive) and sorted by chromosome and position. Reported for each mutation is the disease it causes, the inheritance model, Pubmed ID (PMID) for the reference publication where the causality was initially reported, gene name, gene MIM number, variant site in GRCh37 (chromosome, position, rsID) and the effect of the mutation on cDNA and on amino acid. Also reported is the total number of homozygous and heterozygous Qataris observed harboring this mutation (# Q - Hom & Het, respectively), the overall frequency of the deleterious allele in Qataris, and allele frequency in the Exome Aggregation Consortium (ExAC, total alleles ~63,000). LO: Late Onset, SD: Semi-dominant, M: Mild, RP: Reduced Penetrance. PMID: Pubmed ID. MAF: Minor Allele Frequency. Positions include both GRCh37 and QTRG3 coordinates inferred using HALtools<sup>44</sup> liftover of GRCh37 to QTRG3 alignment produced using progressiveCactus<sup>26</sup>.

#### **Supplemental Figure Legends**

Supplemental Figure 1. Sample analysis flowchart. Shown is an overview of the major analysis steps and samples included in each analysis. From top to bottom and left to right, samples for sequencing in this study include n=215 s living in Qatar and n=1161 Qataris, defined as such based on 3 generations of ancestry in Qatar. Exome sequencing was conducted on n=1268 samples using Illumina instruments and two Agilent SureSelect Human All Exon kits (n=1201 and Qatari on the 51 Mb kit and n=67 Qatari on the 38 Mb kit), hereafter referred to as "Exome38Mb" and "Exome51Mb". Genome sequencing was also conducted for n=108 Qatari samples on an Illumina instrument. Variant calling was conducted for each batch of samples (Exome51Mb, Exome38Mb, genome), and combined into a preliminary SNP and indel call set. Using variant calls within genomic intervals covered in all three batches (within CCDS coding exons targeted by the Agilent SureSelect 38 Mb kit), three preliminary analyses were conducted. The preliminary analysis included (1) identification of optimal batch-specific filters, (2) identification of relatives in the n=1376 samples using a LD-pruned set of SNPs, and (3) population structure analysis (ADMIXTURE and principal components) using a subset of variants also segregating in the database of public samples (Human Origins and 1000 Genomes). Based on the results of preliminary analysis, pruning of non-Qataris (n=215) and  $1^{st}/2^{nd}$  degree relatives (n=156) resulted in n=1005 unrelated Qataris for further analysis, including n=917 exomes (n=64 Exome38Mb and n=853 Exome51Mb), and n=88 genomes. The allele frequencies of the remaining variants was quantified, and a comparison to dbSNP 146 was conducted to identify novel variants and enable database annotation of known variants. Using variants (SNPs and indels) present in over 50% of the n=1005 samples, the GRCh37 human reference genome was modified to incorporate these major alternate alleles (MAA). The value of using the modified reference, or Qatar Reference Genome (QTRG) was then assessed by comparing sequencing depth and variant calls for Qataris not in the n=1005 used to construct the reference. In addition, a catalog of potentially pathogenic variants was constructed by combining the Qatari variant allele frequency information with public database for genes and variants linked to disease and algorithms for predicting variant function and pathogenicity.

**Supplemental Figure 2.** Impact of minimum depth and minimum allele count on novel SNP rate. A total of 1376 samples were sequenced using Illumina technology on three platforms, including genome (n=108), exome sequencing based on enrichment using the Agilent SureSelect 38 Mb targets (Exome38Mb, n=67), and exome sequencing based on enrichment using the Agilent SureSelect 51 Mb targets (Exome51Mb, n=1201). In order to integrate the three datasets, genotypes were generated for a set of variants covered by the three platforms, including CCDS coding exons overlapping the Exome38Mb targets. Variants were filtered using a range of minimum depth and minimum allele count parameters, shown is the impact of these filters on **A**. Mean depth at variant sites, **B**. Mean number of variant sites per sample, and **C**. percentage of novel variants, defined as not present in DbSNP build 146. Dotted line indicates level of consistent novel SNP rate.

**Supplemental Figure 3.** Impact of filters on batch-specific variants. Batch-specific variants. In order to validate the selected minimum depth and minimum allele count for each platform, the proportion of batch-specific variants was compared in variant call data with and without filters applied. Data source is a single Qatari female DNA sample that was sequenced on four platforms (2 exome, 2 genome), including genome sequencing on both the Illumina HiSeq 2500 and Illumina HiSeq X platforms, as well as Illumina sequencing of exome DNA enriched using the Agilent SureSelect Human All Exon 51 Mb and 38 Mb targets. Variant calls were generated using GATK HaplotypeCaller on the four datasets, limited to CCDS coding intervals covered by the four platforms (within 38 Mb targets). Shown are Venn diagrams of **A.** unfiltered variant sites,

**B.** unfiltered novel variant sites (not in DbSNP 146), **C.** filtered variant sites, and **D.** filtered novel variant sites.

Supplemental Figure 4. Impact of filters on sensitivity. In order to determine the impact of batch-specific filters on sensitivity for variant detection and novel SNP rate across a range of depths, variant calls were generated for a quadruple sequenced Qatari using the GATK "dfrac" parameter, which enables variant calling on a subsampling a percentage of reads. The dfracbased calling was conducted for a range of values from 5% to 100%, in 5% increments. At each setting, calls were generated on genomic intervals overlapping between the four platforms four platforms (2 exome, 2 genome), including genome sequencing on both the Illumina HiSeq 2500 and Illumina HiSeq X platforms, as well as Illumina sequencing of exome DNA enriched using the Agilent SureSelect Human All Exon 51 Mb and 38 Mb targets. Variant calls were generated using GATK HaplotypeCaller on the four datasets, limited to CCDS coding intervals covered by the four platforms (within 38 Mb targets). Shown is A. the total number of unfiltered variants (yaxis) in the four platforms across a range of depths (x-axis) color-coded by platform (blue = Exome38Mb, green = Exome51Mb, red = genome on HiSeq 2500, orange = genome on HiSeq X). **B.** total number of filtered variants (y-axis) in the four platforms across a range of depths (xaxis), **C.** the proportion of unfiltered novel variants (y-axis) in the four platforms across a range of depths (x-axis), and **D**. the proportion of filtered novel variants (y-axis) in the four platforms across a range of depths (x-axis).

**Supplemental Figure 5.** Dominant ancestries. In order to infer the dominant ancestry of each of the n=1161 Qatari samples included in this study, and ADMIXTURE analysis was conducted on n=5611 samples, including the n=1161 Qataris included in this study, the n=215 s sampled in Qatar, the Human Origins data (n=1862), and the 1000 Genomes Phase 3 data (n=2373 not in Human Origins). Integration of the datasets resulted in n=2256 SNPs present in all three (n=1376)

from this study, Human Origins, and 1000 Genomes). The ADMIXTURE analysis was conducted with K=12, determined to be optimal in a prior study<sup>17</sup>, resulting in admixture proportions in 12 ancestral populations for each individual. Individuals were assigned to an ancestral population based on their dominant ancestry, and cluster names were assigned based on the major populations present in these clusters. Shown is the ancestry proportion in **A.** the full dataset (n=5611), and a detailed view of the results from the same analysis in **B.** the n=1161 Qatari.

**Supplemental Figure 6.** Principal components analysis. In order to confirm the observed population structure inferred using ADMIXTURE<sup>16,26</sup>, a principal components (PC) analysis<sup>45</sup> was conducted on the n=5611 samples, including n=1161 Qataris, n=215 s living in Qatar, n=1862 Human Origins samples, and n=2373 1000 Genomes Phase 3 samples not in Human Origins. Analysis was conducted using the same n=2256 SNPs used in the ADMIXTURE<sup>16,26</sup> analysis. Each individual is color-coded based on their dominant ancestry (K cluster), with names assigned based on the major populations in the cluster (K=1 European, K=2 East Asian, K=3 Siberian, K=4 South Asian, K=5 Bedouin, K=6 African Pygmy, K=7 Oceanian, K=8 Arab, K=9 Persian, K=10 Sub-Saharan African, K=11 American, K=12 Central Asian). Shown is a plot of **A**. PC1 *vs* PC2 and **B**. PC2 *vs* PC3.

**Supplemental Figure 7.** Relatives in Qatar. In order to compare inferred pedigree sizes between Qataris and non-Qataris, a graph of inferred relatives was produced. Shown are inferred pedigrees for **A.** Qataris and **B.** s, in order of decreasing size. Relationships were inferred between n=1376 samples (including Qataris and s) as described in the Supplemental Methods and Summarized in Supplemental Table IV. Each node represents and individual, and the line connecting two individuals represents the relationship (1<sup>st</sup> degree = straight line, 2<sup>nd</sup> degree = wavy line, 3<sup>rd</sup> degree = dotted line). The nodes are color-coded based on the inferred dominant ancestry in the ADMIXTURE<sup>16,26</sup> analysis.

#### **Online Resources**

**Online Resource 1. Prevalence and Function of Qatari Variants.** Tab-delimited file including allele frequency in the Qatari population, number of homozygous and heterozygous individuals, functional annotation, and links to databases of gene and variant function for 20.9 million SNPs identified in 88 unrelated Qatari genomes 917 unrelated Qatari exomes. Available for download is the full list of variants, as well as subsets of category 1, category 2, and category 3 variants, as described in Table II. Variant database can be accessed at http://geneticmedicine.weill.cor-nell.edu/Genome/Online.Resource.1/

# **Online Resource 2. Qatari Reference Genome (QTRG1, QTRG2, QTRG3).** Human reference genome based on GRCh37 where the major alternate allele identified in 88 unrelated Qatari genomes 917 unrelated Qatari exomes replaced the reference allele SNP and indel sites. Accessible at http://geneticmedicine.weill.cornell.edu/Genome/Online.Resource.2/.

**Online Resource 3. Precision medicine tools for Qatari genomes.** Genome interpretation analysis workflow based on GATK Best Practices<sup>8</sup> for an individual Qatari genome, coded in Python. Accessible at http://geneticmedicine.weill.cornell.edu/Genome/Online.Resource.3/. **Online Resource 4. All variants observed in unrelated Qataris.** Genotypes for variant sites (with respect to GRCh37) observed in 1376 Qataris, in VCF format before application of platform specific filters. Accessible at http://geneticmedicine.weill.cornell.edu/Genome/Online.Resource.4/.

**Online Resource 5. Segregating sites in unrelated Qataris.** Genotypes for variant sites polymorphic in 1005 unrelated Qataris, in PLINK format<sup>12</sup>. Accessible at http://geneticmedicine.weill.cornell.edu/Genome/Online.Resource.5/.

#### **Supplemental References**

- 1. Hunter-Zinck H, Musharoff S, Salit J, Al-Ali KA, Chouchane L, Gohar A *et al.* Population genetic structure of the people of Qatar. *Am J Hum Genet* 2010; **87:** 17-25.
- 2. Omberg L, Salit J, Hackett N, Fuller J, Matthew R, Chouchane L *et al.* Inferring genomewide patterns of admixture in Qataris using fifty-five ancestral populations. *BMC Genet* 2012; **13:** 49.
- 3. Rodriguez-Flores JL, Fuller J, Hackett NR, Salit J, Malek JA, Al-Dous E *et al.* Exome sequencing of only seven qataris identifies potentially deleterious variants in the qatari population. *PLoS One* 2012; **7:** e47614.
- 4. Rodriguez-Flores JL, Fakhro K, Hackett NR, Salit J, Fuller J, gosto-Perez F *et al.* Exome sequencing identifies potential risk variants for Mendelian disorders at high prevalence in Qatar. *Hum Mutat* 2014; **35:** 105-116.
- 5. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. *Genetics* 2000; **155**: 945-959.
- 6. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG *et al.* Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* 2008; **456:** 53-59.
- 7. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25:** 1754-1760.
- 8. GATK development team. GATK Best Practices. <u>https://www.broadinsti-tute.org/gatk/guide/best-practices</u>. 2015. (last accessed 3/7/16)
- 9. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009; **25**: 2078-2079.
- 10. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011; **43:** 491-498.
- 11. Farrell CM, O'Leary NA, Harte RA, Loveland JE, Wilming LG, Wallin C *et al.* Current status and new features of the Consensus Coding Sequence database. *Nucleic Acids Res* 2014; **42:** D865-D872.
- 12. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81:** 559-575.
- 13. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015; **4**: 7.

- Sulonen AM, Ellonen P, Almusa H, Lepisto M, Eldfors S, Hannula S *et al.* Comparison of solution-based exome capture methods for next generation sequencing. *Genome Biol* 2011; 12: R94.
- 15. Chilamakuri CS, Lorenz S, Madoui MA, Vodak D, Sun J, Hovig E *et al.* Performance comparison of four exome capture systems for deep sequencing. *BMC Genomics* 2014; **15**: 449.
- 16. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. *Genome Res* 2009; **19:** 1655-1664.
- 17. Rodriguez-Flores JL, Fakhro K, gosto-Perez F, Ramstetter MD, Arbiza L, Vincent TL *et al.* Indigenous Arabs are descendants of the earliest split from ancient Eurasian populations. *Genome Res* 2016; **26:** 151-162.
- 18. Sandridge AL, Takeddin J, Al-Kaabi E, Frances Y. Consanguinity in Qatar: knowledge, attitude and practice in a population born between 1946 and 1991. *J Biosoc Sci* 2010; **42:** 59-82.
- 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. *Bioinformatics* 2010; **26**: 2867-2873.
- 20. McPeek MS, Sun L. Statistical tests for detection of misspecified relationships by use of genome-screen data. *Am J Hum Genet* 2000; **66:** 1076-1094.
- 21. Zhuang Z, Gusev A, Cho J, Pe'er I. Detecting identity by descent and homozygosity mapping in whole-exome sequencing data. *PLoS One* 2012; **7:** e47618.
- 22. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA *et al.* The variant call format and VCFtools. *Bioinformatics* 2011; **27:** 2156-2158.
- 23. Pearson WR, Lipman DJ. Improved tools for biological sequence comparison. *Proc Natl Acad Sci U S A* 1988; **85:** 2444-2448.
- 24. GitHub. Picard. http://broadinstitute.github.io/picard/ . 2015. (last accessed 3/7/16)
- 25. Cavanaugh DJ, Cann CE. Brisk walking does not stop bone loss in postmenopausal women. *Bone* 1988; **9:** 201-204.
- 26. Paten B, Earl D, Nguyen N, Diekhans M, Zerbino D, Haussler D. Cactus: Algorithms for genome multiple sequence alignment. *Genome Res* 2011; **21**: 1512-1528.
- 27. Kurtz S, Phillippy A, Delcher AL, Smoot M, Shumway M, Antonescu C *et al.* Versatile and open software for comparing large genomes. *Genome Biol* 2004; **5:** R12.
- 28. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S *et al.* Ensembl 2015. *Nucleic Acids Res* 2015; **43**: D662-D669.

- 29. Cingolani P, Platts A, Wang IL, Coon M, Nguyen T, Wang L *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. *Fly (Austin )* 2012; **6:** 80-92.
- 30. Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders. *Nucleic Acids Res* 2015; **43**: D789-D798.
- 31. Stenson PD, Ball EV, Mort M, Phillips AD, Shaw K, Cooper DN. The Human Gene Mutation Database (HGMD) and its exploitation in the fields of personalized genomics and molecular evolution. *Curr Protoc Bioinformatics* 2012; Chapter 1: Unit1.
- 32. Yu W, Yesupriya A, Wulf A, Hindorff LA, Dowling N, Khoury MJ *et al.* GWAS Integrator: a bioinformatics tool to explore human genetic associations reported in published genome-wide association studies. *Eur J Hum Genet* 2011; **19**: 1095-1099.
- 33. Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB *et al.* PharmGKB: the Pharmacogenetics Knowledge Base. *Nucleic Acids Res* 2002; **30**: 163-165.
- 34. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM *et al.* ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res* 2014; **42:** D980-D985.
- 35. Groza T, Kohler S, Moldenhauer D, Vasilevsky N, Baynam G, Zemojtel T *et al.* The Human Phenotype Ontology: Semantic Unification of Common and Rare Disease. *Am J Hum Genet* 2015; **97:** 111-124.
- 36. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 2000; **15:** 7-12.
- 37. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**: 405-424.
- 38. Henn BM, Botigue LR, Bustamante CD, Clark AG, Gravel S. Estimating the mutation load in human genomes. *Nat Rev Genet* 2015; **16:** 333-343.
- 39. Kohler S, Doelken SC, Mungall CJ, Bauer S, Firth HV, Bailleul-Forestier I *et al.* The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. *Nucleic Acids Res* 2014; **42:** D966-D974.
- 40. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012; **491:** 56-65.
- 41. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO *et al.* A global reference for human genetic variation. *Nature* 2015; **526:** 68-74.

- 42. Lazaridis I, Patterson N, Mittnik A, Renaud G, Mallick S, Kirsanow K *et al.* Ancient human genomes suggest three ancestral populations for present-day Europeans. *Nature* 2014; **513:** 409-413.
- 43. Python. <u>www.phython.org</u> . 2016. (last accessed 3/7/16)
- 44. Hickey G, Paten B, Earl D, Zerbino D, Haussler D. HAL: a hierarchical format for storing and analyzing multiple genome alignments. *Bioinformatics* 2013; **29:** 1341-1342.
- 45. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006; **38**: 904-909.





Mean, ordered by platform, minimum allele count (AC), minimum depth (DP)



Mean, ordered by platform, minimum allele count (AC), minimum depth (DP)



Mean, ordered by platform, minimum allele count (AC), minimum depth (DP)

HiSeq 2500 HiSeq 2500 HiSeq 2500 HiSeq 2500 50 Mb WXS WGS HiSeq 2000 **50 Mb WXS** WGS (n=18,004) (n=18,596) HiSeq X HiSeq 2000 38 Mb WXS (n=16,882) WGS **38 Mb WXS** (n=18,560) (n=18,761) (n=16,525) 365 (1.8%) 221 (1.1%) 80 (0.4%) 301 (1.6%) **43** (0.2%) 63 (0.3%) 236 **123** (0.7%) 67 (0.4%) 328 (1.7%) 984 (4.8%) 500 (2.4%) 94 (0.5%) 651 (3.2%) 368 (2%) 176 (0.9%) 126 (0.7%) 1264 (6.7%) **16742** (81.3%) 62 (0.3%) **17** (0.1%) 15159 (80.6%) **43** (0.2%) 16 (0.1%) 29 (0.1%) 547 (2.7%) 660 3.5% 47 (0 . 2% 39 (0.2%) 55 (0.3%) **B.** Novel variants (unfiltered) D. Novel variants (platform-specific filters applied) HiSeq 2500 **HiSeq 2500** HiSeq 2500 HiSeq 2500 50 Mb WXS WGS 50 Mb WXS WGS



HiSeq 2000 HiSeq 2000 (n=373) (n=169) HiSeq X (n=91) (n=112) **HiSeq X 38 Mb WXS 38 Mb WXS** WGS WGS (n=458) (n=102) (n=320) 236 (26.3%) **19** (2.1%) (n=109) 4 (3.1%) 7 (5.3%) **0** (0%) 10 (1.1%) 2 (0.2%) 1 (0.8%) 1 (0.8%) 3 (2.3%) 321 (35.7%) 166 (18.5%) **6** (4.6%) 5 (3.8%) 8 (0.9%) 1 (0.1%) **3** (2.3%) 8 (6.1%) **123** (13.7%) 72 (55%) **0** (0%) 2 (0.2%) **0** (0%) 1 (0.8%) 8 (0.9%) 1 (0.1%) 18 13.7%) 1 (0.8%) 2 (0.2%) 1 (0.8%)



C. Variants (platform-specific filters applied)
## A. Variants (unfiltered)



## C. Novel variant rate (unfiltered)





## B. Variants (platform-specific filters applied)



## D. Novel variant rate (platform-specific filters applied)



Exome38Mb Genome HiSeq 2500 Genome HiSeq X Exome51Mb 



Qatari, 1000 Genomes, and Human Origins individuals (n=5611), sorted by dominant ancestry cluster (K)



Qatari individuals (n=1161), sorted by dominant ancestry cluster (K)

A. PC1 and PC2 of genetic variation in Qatari, non-Qatari living in Qatar, 1000 Genomes Phase 3, and Human Origins (n=5611), color-coded by dominant ancestry cluster (K)







